顔写真

フナキ ヨシヒト
船木 善仁
Yoshihito Funaki
所属
サイクロトロン・ラジオアイソトープセンター 核薬学研究部
職名
講師
学位
  • 博士(医学)(東北大学)

  • 修士(薬学)(東北大学)

経歴 3

  • 2014年4月 ~ 継続中
    東北大学 サイクロトロン・ラジオアイソトープセンター 講師

  • 2007年4月 ~ 2014年3月
    東北大学サイクロトロン・ラジオアイソトープセンター 助教

  • 1994年4月 ~ 2007年3月
    東北大学サイクロトロン・ラジオアイソトープセンター 助手

学歴 2

  • 東北大学 薬学研究科 核薬学

    ~ 1993年3月

  • 東北大学 薬学部 衛生化学

    ~ 1991年3月

委員歴 2

  • 日本アイソトープ協会放射線安全取扱部会 東北支部委員

    2022年4月 ~ 継続中

  • 第54回日本核医学会学術総会 プログラム委員

    2014年11月 ~

所属学協会 3

  • 日本アイソトープ協会

    2023年4月 ~ 継続中

  • 日本核医学会

  • 日本薬学会

研究キーワード 2

  • PET

  • 放射性薬剤

研究分野 3

  • ライフサイエンス / 薬理学 /

  • ライフサイエンス / 薬系化学、創薬科学 /

  • ライフサイエンス / 放射線科学 /

論文 132

  1. Amyloid accumulation in cases of suspected comorbid cerebral amyloid angiopathy and isolated cortical venous thrombosis. 国際誌

    Yuya Kobayashi, Kotaro Hiraoka, Ryo Itabashi, Takuya Saito, Yuichi Kawabata, Yukako Yazawa, Yoshihito Funaki, Shozo Furumoto, Nobuyuki Okamura, Katsutoshi Furukawa, Aiko Ishiki, Hiroyuki Arai, Kazuhiko Yanai, Manabu Tashiro, Yoshiki Sekijima

    Journal of the neurological sciences 457 122892-122892 2024年1月20日

    DOI: 10.1016/j.jns.2024.122892  

    詳細を見る 詳細を閉じる

    BACKGROUND AND AIM: The differentiation of isolated cortical venous thrombosis (ICVT) from cerebral amyloid angiopathy (CAA) can be difficult because both diseases share similar neurological symptoms and imaging findings. N-methyl-11C-2-(4'-methylaminophenyl)-6-hydroxybenzo-thiazole (11C-PiB) positron emission tomography (PET) functions as a diagnostic modality for CAA by detecting amyloid deposition. The present prospective study evaluated amyloid deposition using 11C-PiB-PET in consecutive patients with suspected ICVT. METHOD: This study was a prospective observational study. Patients who attended or were hospitalized between May 2019 and March 2020 were included in the analysis. Consecutive patients who met the criteria for suspicion of ICVT were enrolled in the study, and the clinical course, symptoms, imaging findings (including magnetic resonance imaging), and the 11C-PiB-PET findings of each case were analyzed. RESULTS: The study cohort included four patients (64-82 years of age, all women). In one younger patient, 11C-PiB-PET afforded no findings suggestive of CAA, whereas the remaining three patients exhibited 11C-PiB-PET findings suggestive of CAA. CONCLUSION: Although 11C-PiB-PET would be a reasonable modality for distinguishing ICVT from CAA, especially in younger patients, it might be difficult to differentiate ICVT from CAA in elderly patients because of the potential deposition of amyloid. CLINICAL TRIAL REGISTRATION: URL: https://www.umin.ac.jp/ctr/ Unique identifier: UMIN 000037101.

  2. The neuromodulatory role of dopamine in improved reaction time by acute cardiovascular exercise. 国際誌

    Soichi Ando, Toshihiko Fujimoto, Mizuki Sudo, Shoichi Watanuki, Kotaro Hiraoka, Kazuko Takeda, Yoko Takagi, Daisuke Kitajima, Kodai Mochizuki, Koki Matsuura, Yuki Katagiri, Fairuz Mohd Nasir, Yuchen Lin, Mami Fujibayashi, Joseph T Costello, Terry McMorris, Yoichi Ishikawa, Yoshihito Funaki, Shozo Furumoto, Hiroshi Watabe, Manabu Tashiro

    The Journal of physiology 2024年1月2日

    DOI: 10.1113/JP285173  

    詳細を見る 詳細を閉じる

    Acute cardiovascular physical exercise improves cognitive performance, as evidenced by a reduction in reaction time (RT). However, the mechanistic understanding of how this occurs is elusive and has not been rigorously investigated in humans. Here, using positron emission tomography (PET) with [11 C]raclopride, in a multi-experiment study we investigated whether acute exercise releases endogenous dopamine (DA) in the brain. We hypothesized that acute exercise augments the brain DA system, and that RT improvement is correlated with this endogenous DA release. The PET study (Experiment 1: n = 16) demonstrated that acute physical exercise released endogenous DA, and that endogenous DA release was correlated with improvements in RT of the Go/No-Go task. Thereafter, using two electrical muscle stimulation (EMS) studies (Experiments 2 and 3: n = 18 and 22 respectively), we investigated what triggers RT improvement. The EMS studies indicated that EMS with moderate arm cranking improved RT, but RT was not improved following EMS alone or EMS combined with no load arm cranking. The novel mechanistic findings from these experiments are: (1) endogenous DA appears to be an important neuromodulator for RT improvement and (2) RT is only altered when exercise is associated with central signals from higher brain centres. Our findings explain how humans rapidly alter their behaviour using neuromodulatory systems and have significant implications for promotion of cognitive health. KEY POINTS: Acute cardiovascular exercise improves cognitive performance, as evidenced by a reduction in reaction time (RT). However, the mechanistic understanding of how this occurs is elusive and has not been rigorously investigated in humans. Using the neurochemical specificity of [11 C]raclopride positron emission tomography, we demonstrated that acute supine cycling released endogenous dopamine (DA), and that this release was correlated with improved RT. Additional electrical muscle stimulation studies demonstrated that peripherally driven muscle contractions (i.e. exercise) were insufficient to improve RT. The current study suggests that endogenous DA is an important neuromodulator for RT improvement, and that RT is only altered when exercise is associated with central signals from higher brain centres.

  3. Positron annihilation lifetime measurement with TOF-PET detectors: feasibility of Iodine-124 use

    Sodai Takyu, Hayato Ikeda, Hidekatsu Wakizaka, Fumihiko Nishikido, Ken-ichiro Matsumoto, Hideaki Tashima, Hisashi Suzuki, Yoshihito Funaki, Hiroshi Watabe, Miwako Takahashi, Taiga Yamaya

    Applied Physics Express 16 (11) 116001-116001 2023年11月1日

    出版者・発行元:IOP Publishing

    DOI: 10.35848/1882-0786/ad047c  

    ISSN:1882-0778

    eISSN:1882-0786

    詳細を見る 詳細を閉じる

    Abstract Positronium (Ps) imaging is getting attention for nuclear medicine applications, but appropriate radionuclides have not been evaluated systematically. This paper investigated the use of <sup>124</sup>I, which is a positron emitter with 603 keV prompt gamma ray emission with a fraction of 11.7%. The accuracy of positron annihilation lifetime measurement with <sup>124</sup>I was compared with <sup>22</sup>Na, which is often used in positron annihilation lifetime measurement, for certified reference materials. Results obtained with TOF-PET detectors suggested that the accuracy of the lifetime value estimation was slightly worse than that for <sup>22</sup>Na, while the positron annihilation lifetime measurement using <sup>124</sup>I was a feasible choice.

  4. Noninvasive estimation of human radiation dosimetry of 18F-FDG by whole-body small animal PET imaging in rats. 国際誌 査読有り

    Miho Shidahara, Yoshihito Funaki, Hiroshi Watabe

    Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine 181 110071-110071 2022年3月

    DOI: 10.1016/j.apradiso.2021.110071  

    詳細を見る 詳細を閉じる

    PURPOSE: Small animal PET provides the biodistribution of administrated radiotracer in vivo and have a potential to contribute on dosimetry study. The aim of this study is to investigate the effect of region-of-interest (ROI)-delineation in whole-body rat PET image toward non-invasive estimation of human dosimetry of 18F-FDG. METHOD: After administration of 18F-FDG (averaged 11.7 MBq), 3.5-h PET and 20-min CT scans were sequentially performed for three rats by Clairvivo PET/CT system. Seven source organs, and the remainder of the body, were studied to extrapolate %ID(t) and estimate time-integrated activity coefficients [kBq-h/MBq] in human. The mean absorbed dose in each target organ and the effective dose were estimated by MIRD method. Effects of ROI-definitions on both extrapolated %ID(t) in human and estimated doses were also investigated by using (i) small ROIs of high uptake region and (ii) whole organ ROIs. RESULTS: Averaged effective doses of 18F-FDG in human by using high-uptake and whole-organ ROIs were 27.8 ± 6.54 and 19.3 ± 2.72 μSv/MBq, respectively. CONCLUSION: The use of small animal PET scanner, which allows repeatedly PET scans, have a potential to contribute on the reduction of the number of experimental animals. However, the ways of ROI drawing influences on the estimated effective dose and safe-side ROI definition may be preferred.

  5. 健常者を対象としたPET診断薬<sup>18</sup>F-SMBT-1の全身臓器における生理的集積の観察

    石岡 有生, 四月朔日 聖一, 平岡 宏太良, 石川 洋一, 船木 善仁, 原田 龍一, 岡村 信行, 荒井 啓行, 古本 祥三, 谷内 一彦, 渡部 浩司, 田代 学

    日本臨床薬理学会学術総会抄録集 42 3-P-T-4 2021年

    出版者・発行元:一般社団法人 日本臨床薬理学会

    DOI: 10.50993/jsptsuppl.42.0_3-p-t-4  

    eISSN:2436-5580

    詳細を見る 詳細を閉じる

    【目的】モノアミン酸化酵素B(MAO-B)は様々な臓器に分布して多様な機能を果たしているが、ヒトの全身分布の詳細はまだ十分に明らかにされていない。また最近では、アルツハイマー病患者の脳における神経炎症の一所見として増大する反応性アストロサイトにもMAO-Bが高発現することが知られている。我々は、MAO-Bに特異的に結合する新規PET診断薬剤<sup>18</sup>F-SMBT-1を開発し、ヒトにおいて脳を含む全身臓器のMAO-B分布に関する基礎データを構築するために初期臨床試験を開始した。【方法】健常成人男性4名(20~50歳代)を対象として、<sup>18</sup>F-SMBT-1のトレーサーを約185 MBq投与して、適宜休憩をはさみながら約5時間の全身PET測定を断続的に行った。PET画像をMRI画像に重ね合わせて各臓器への集積値を計測し、その時間的変化のパターンを調べた。 【結果・考察】PET薬剤<sup>18</sup>F-SMBT-1は、薬剤投与初期(最初の5分間)にすみやかに脳、心臓、胃、腎臓、消化管等に分布し、投与後から30分までは比較的高い取り込みを示しつつ、徐々に減少した。その後、肝臓および胆嚢に強い集積が観察され、薬剤投与後期には胆嚢、小腸~大腸、膀胱等に強い集積を示した。胆嚢の集積ピーク値は膀胱の10倍程度となった。また、全身の主要臓器における薬剤集積の変化に被験者間で大きな差異は認められなかった。小腸~大腸の集積所見については、胆汁排泄により薬剤が総肝管を経由し腸管に移動することが結果に影響している可能性が考えられ、生理的集積と排泄に伴う消化管集積が混在していると推測された。【結論】<sup>18</sup>F-SMBT-1は胆汁排泄の割合が高い薬剤であることがわかった。また、全身臓器のMAO-Bマッピングの目的に十分利用可能な薬剤であるとともに、脳マッピングのために十分な量の脳内分布があることがわかった。

  6. 18F-THK5351 Positron Emission Tomography Imaging in Neurodegenerative Tauopathies. 国際誌 査読有り

    Michinori Ezura, Akio Kikuchi, Nobuyuki Okamura, Aiko Ishiki, Takafumi Hasegawa, Ryuichi Harada, Shoichi Watanuki, Yoshihito Funaki, Kotaro Hiraoka, Toru Baba, Naoto Sugeno, Shun Yoshida, Junpei Kobayashi, Michiko Kobayashi, Ohito Tano, Shun Ishiyama, Takaaki Nakamura, Ichiro Nakashima, Shunji Mugikura, Ren Iwata, Yasuyuki Taki, Katsutoshi Furukawa, Hiroyuki Arai, Shozo Furumoto, Manabu Tashiro, Kazuhiko Yanai, Yukitsuka Kudo, Atsushi Takeda, Masashi Aoki

    Frontiers in aging neuroscience 13 761010-761010 2021年

    DOI: 10.3389/fnagi.2021.761010  

    詳細を見る 詳細を閉じる

    Introduction: We aimed to determine whether in vivo tau deposits and monoamine oxidase B (MAO-B) detection using 18F-THK5351 positron emission tomography (PET) can assist in the differential distribution in patients with corticobasal syndrome (CBS), progressive supranuclear palsy (PSP), and Alzheimer's disease (AD) and whether 18F-THK5351 retention of lesion sites in CBS and PSP can correlate with clinical parameters. Methods: 18F-THK5351 PET was performed in 35 participants, including 7, 9, and 10 patients with CBS, PSP, and AD, respectively, and 9 age-matched normal controls. In CBS and PSP, cognitive and motor functions were assessed using the Montreal Cognitive Assessment, Addenbrooke's Cognitive Examination-Revised, and Frontal Assessment Battery, Unified Parkinson's Disease Rating Scale Motor Score, and PSP Rating Scale. Results: 18F-THK5351 retention was observed in sites susceptible to disease-related pathologies in CBS, PSP, and AD. 18F-THK5351 uptake in the precentral gyrus clearly differentiated patients with CBS from those with PSP and AD. Furthermore, 18F-THK5351 uptake in the inferior temporal gyrus clearly differentiated patients with AD from those with CBS and PSP. Regional 18F-THK5351 retention was associated with the cognitive function in CBS and PSP. Conclusion: Measurement of the tau deposits and MAO-B density in the brain using 18F-THK5351 may be helpful for the differential diagnosis of tauopathies and for understanding disease stages.

  7. Non-invasive imaging of radiocesium dynamics in a living animal using a positron-emitting 127Cs tracer 査読有り

    Nobuo Suzui, Takuya Shibata, Yong-Gen Yin, Yoshihito Funaki, Keisuke Kurita, Hiroyuki Hoshina, Mitsutaka Yamaguchi, Shu Fujimaki, Noriaki Seko, Hiroshi Watabe, Naoki Kawachi

    Scientific Reports 10 (1) 2020年12月

    出版者・発行元:Springer Science and Business Media LLC

    DOI: 10.1038/s41598-020-73351-2  

    ISSN:2045-2322

    eISSN:2045-2322

    詳細を見る 詳細を閉じる

    <title>Abstract</title> Visualizing the dynamics of cesium (Cs) is desirable to understand the impact of radiocesium when accidentally ingested or inhaled by humans. However, visualization of radiocesium in vivo is currently limited to plants. Herein, we describe a method for the production and purification of <sup>127</sup>Cs and its use in visualizing Cs dynamics in a living animal. The positron-emitting nuclide <sup>127</sup>Cs was produced using the <sup>127</sup>I (α, 4n) <sup>127</sup>Cs reaction, which was induced by irradiation of sodium iodide with a <sup>4</sup>He<sup>2+</sup> beam from a cyclotron. We excluded sodium ions by using a material that specifically adsorbs Cs as a purification column and successfully eluted <sup>127</sup>Cs by flowing a solution of ammonium sulfate into the column. We injected the purified <sup>127</sup>Cs tracer solution into living rats and the dynamics of Cs were visualized using positron emission tomography; the distributional images showed the same tendency as the results of previous studies using disruptive methods. Thus, this method is useful for the non-invasive investigation of radiocesium in a living animal.

  8. Longitudinal changes in 18 F-THK5351 positron emission tomography in corticobasal syndrome. 国際誌 査読有り

    M Ezura, A Kikuchi, A Ishiki, N Okamura, T Hasegawa, R Harada, S Watanuki, Y Funaki, K Hiraoka, T Baba, N Sugeno, R Oshima, S Yoshida, J Kobayashi, M Kobayashi, O Tano, I Nakashima, S Mugikura, R Iwata, Y Taki, K Furukawa, H Arai, S Furumoto, M Tashiro, K Yanai, Y Kudo, A Takeda, M Aoki

    European journal of neurology 26 (9) 1205-1211 2019年9月

    DOI: 10.1111/ene.13966  

    詳細を見る 詳細を閉じる

    BACKGROUND AND PURPOSE: Corticobasal syndrome (CBS) is pathologically characterized by tau deposits in neuronal and glial cells and by reactive astrogliosis. In several neurodegenerative disorders, 18 F-THK5351 has been observed to bind to reactive astrocytes expressing monoamine oxidase B. In this study, the aim was to investigate the progression of disease-related pathology in the brains of patients with CBS using positron emission tomography with 18 F-THK5351. METHODS: Baseline and 1-year follow-up imaging were acquired using magnetic resonance imaging and positron emission tomography with 18 F-THK5351 in 10 subjects: five patients with CBS and five age-matched normal controls (NCs). RESULTS: The 1-year follow-up scan images revealed that 18 F-THK5351 retention had significantly increased in the superior parietal gyrus of the patients with CBS compared with the NCs. The median increases in 18 F-THK5351 accumulation in the patients with CBS were 6.53% in the superior parietal gyrus, 4.34% in the precentral gyrus and 4.33% in the postcentral gyrus. In contrast, there was no significant increase in the regional 18 F-THK5351 retention in the NCs. CONCLUSIONS: Longitudinal increases in 18 F-THK5351 binding can be detected over a short interval in the cortical sites of patients with CBS. A monoamine oxidase B binding radiotracer could be useful in monitoring the progression of astrogliosis in CBS.

  9. Brain histamine H1 receptor occupancy after oral administration of desloratadine and loratadine. 国際誌 査読有り

    Tadaho Nakamura, Kotaro Hiraoka, Ryuichi Harada, Takuro Matsuzawa, Yoichi Ishikawa, Yoshihito Funaki, Takeo Yoshikawa, Manabu Tashiro, Kazuhiko Yanai, Nobuyuki Okamura

    Pharmacology research & perspectives 7 (4) e00499 2019年8月

    DOI: 10.1002/prp2.499  

    詳細を見る 詳細を閉じる

    Some histamine H1 receptor (H1R) antagonists induce adverse sedative reactions caused by blockade of histamine transmission in the brain. Desloratadine is a second-generation antihistamine for treatment of allergic disorders. Its binding to brain H1Rs, which is the basis of sedative property of antihistamines, has not been examined previously in the human brain by positron emission tomography (PET). We examined brain H1R binding potential ratio (BPR), H1R occupancy (H1RO), and subjective sleepiness after oral desloratadine administration in comparison to loratadine. Eight healthy male volunteers underwent PET imaging with [11C]-doxepin, a PET tracer for H1Rs, after a single oral administration of desloratadine (5 mg), loratadine (10 mg), or placebo in a double-blind crossover study. BPR and H1RO in the cerebral cortex were calculated, and plasma concentrations of loratadine and desloratadine were measured. Subjective sleepiness was quantified by the Line Analogue Rating Scale (LARS) and the Stanford Sleepiness Scale (SSS). BPR was significantly lower after loratadine administration than after placebo (0.504 ± 0.074 vs 0.584 ± 0.059 [mean ± SD], P < 0.05), but BPR after desloratadine administration was not significantly different from BPR after placebo (0.546 ± 0.084 vs 0.584 ± 0.059, P = 0.250). The plasma concentration of loratadine was negatively correlated with BPR in subjects receiving loratadine, but that of desloratadine was not correlated with BPR. Brain H1ROs after desloratadine and loratadine administration were 6.47 ± 10.5% and 13.8 ± 7.00%, respectively (P = 0.103). Subjective sleepiness did not significantly differ among subjects receiving the two antihistamines and placebo. At therapeutic doses, desloratadine did not bind significantly to brain H1Rs and did not induce any significant sedation.

  10. Na18F accumulates on the compressive side of peri-implant bone under immediate loading 査読有り

    Miou Yamamoto, Toru Ogawa, Masayoshi Yokoyama, Yoshihito Funaki, Kenta Shobara, Aya Shibamoto, Juan Ramón Vanegas Sáenz, Keiichi Sasaki

    Odontology 106 (3) 232-237 2018年7月1日

    出版者・発行元:Springer Tokyo

    DOI: 10.1007/s10266-017-0327-0  

    ISSN:1618-1255 1618-1247

    詳細を見る 詳細を閉じる

    This study aimed to examine the dynamic change in bone metabolism by immediate loading in several sites around implants using high-resolution Na18F-PET scan. Two titanium implants (Ø 1.2 mm) were inserted parallel to each other in the right tibiae of Wistar rats (n = 4). The left tibia was set as control side. One day after insertion, closed coil springs of 4.0 N were attached to the expose superior portions of the implants to apply a continuous mechanical stress. The rats with fluorine-18 (18F) ion (5 mCi/rat) intravenously injected were scanned by PET scanner at 4, 7, 14, 28 days after load application. Round region of interests (ROIs) were set around the distal implant of the right tibia (loaded side) and same site (control) of the left tibia. Furthermore, four rectangular ROIs were set at the superior and inferior parts of traction side (mesial) and opposite side (distal) of the distal implant. Longitudinal dynamic changes in bone metabolism were evaluated by examination of the accumulation count of 18F ion at each ROI. The uptake values of ROIs (loaded side) initially increased until 7 days, and they gradually decreased from the peak level to the pre-loading level despite a static force being applied to the implants. In cancellous bone, the uptake values at the superior part of traction side and inferior part of opposite side showed significantly high value compared with those at other parts. In conclusion, immediate loading to the implant initially enhanced bone metabolism around it, especially at the part with compressive stress. Peri-implant bone metabolism varies according to different loading conditions.

  11. Neuroimaging-pathological correlations of [18F]THK5351 PET in progressive supranuclear palsy. 国際誌 査読有り

    Aiko Ishiki, Ryuichi Harada, Hideaki Kai, Naomi Sato, Tomoko Totsune, Naoki Tomita, Shoichi Watanuki, Kotaro Hiraoka, Yoichi Ishikawa, Yoshihito Funaki, Ren Iwata, Shozo Furumoto, Manabu Tashiro, Hironobu Sasano, Tetsuyuki Kitamoto, Yukitsuka Kudo, Kazuhiko Yanai, Katsutoshi Furukawa, Nobuyuki Okamura, Hiroyuki Arai

    Acta neuropathologica communications 6 (1) 53-53 2018年6月29日

    DOI: 10.1186/s40478-018-0556-7  

    詳細を見る 詳細を閉じる

    Recent positron emission tomography (PET) studies have demonstrated the accumulation of tau PET tracer in the affected region of progressive supranuclear palsy (PSP) cases. To confirm the binding target of radiotracer in PSP, we performed an imaging-pathology correlation study in two autopsy-confirmed PSP patients who underwent [18F]THK5351 PET before death. One patient with PSP Richardson syndrome showed elevated tracer retention in the globus pallidus and midbrain. In a patient with PSP-progressive nonfluent aphasia, [18F]THK5351 retention also was observed in the cortical areas, particularly the temporal cortex. Neuropathological examination confirmed PSP in both patients. Regional [18F]THK5351 standardized uptake value ratio (SUVR) in antemortem PET was significantly correlated with monoamine oxidase-B (MAO-B) level, reactive astrocytes density, and tau pathology at postmortem examination. In in vitro autoradiography, specific THK5351 binding was detected in the area of antemortem [18F]THK5351 retention, and binding was blocked completely by a reversible selective MAO-B inhibitor, lazabemide, in brain samples from these patients. In conclusion, [18F]THK5351 PET signals reflect MAO-B expressing reactive astrocytes, which may be associated with tau accumulation in PSP.

  12. Correlations of 18F-THK5351 PET with Postmortem Burden of Tau and Astrogliosis in Alzheimer Disease. 国際誌 査読有り

    Ryuichi Harada, Aiko Ishiki, Hideaki Kai, Naomi Sato, Katsutoshi Furukawa, Shozo Furumoto, Tetsuro Tago, Naoki Tomita, Shoichi Watanuki, Kotaro Hiraoka, Yoichi Ishikawa, Yoshihito Funaki, Tadaho Nakamura, Takeo Yoshikawa, Ren Iwata, Manabu Tashiro, Hironobu Sasano, Tetsuyuki Kitamoto, Kazuhiko Yanai, Hiroyuki Arai, Yukitsuka Kudo, Nobuyuki Okamura

    Journal of nuclear medicine : official publication, Society of Nuclear Medicine 59 (4) 671-674 2018年4月

    DOI: 10.2967/jnumed.117.197426  

    ISSN:0161-5505

    詳細を見る 詳細を閉じる

    Clinical PET studies using 18F-THK5351 have demonstrated significant tracer retention in sites susceptible to tau burden in Alzheimer disease (AD). However, the in vivo PET signal to reflect tau aggregates remains controversial. Methods: We examined the spatial pattern of tracer binding, amyloid-β, tau, and gliosis in an autopsy-confirmed AD patient who underwent 18F-THK5351 and 11C-Pittsburgh compound B PET before death. Results: Regional in vivo 18F-THK5351 retention was significantly correlated with the density of tau aggregates in the neocortex and monoamine oxidase-B in the whole brain, but not correlated with that of insoluble amyloid-β. Furthermore, significant association was observed between the density of tau aggregates, monoamine oxidase-B, and glial fibrillary acidic protein, suggesting that neocortical tau would strongly influence the formation of reactive astrocytes. Conclusion:18F-THK5351 PET may have limited utility as a biomarker of tau pathology in AD; however, it could be used to monitor the neuroinflammatory processes in the living brain.

  13. Renal Denervation Suppresses Coronary Hyperconstricting Responses After Drug-Eluting Stent Implantation in Pigs In Vivo Through the Kidney-Brain-Heart Axis. 国際誌 査読有り

    Hironori Uzuka, Yasuharu Matsumoto, Kensuke Nishimiya, Kazuma Ohyama, Hideaki Suzuki, Hirokazu Amamizu, Susumu Morosawa, Michinori Hirano, Tomohiko Shindo, Yoku Kikuchi, Kiyotaka Hao, Takashi Shiroto, Kenta Ito, Jun Takahashi, Koji Fukuda, Satoshi Miyata, Yoshihito Funaki, Hatsue Ishibashi-Ueda, Satoshi Yasuda, Hiroaki Shimokawa

    Arteriosclerosis, thrombosis, and vascular biology 37 (10) 1869-1880 2017年10月

    DOI: 10.1161/ATVBAHA.117.309777  

    ISSN:1079-5642

    詳細を見る 詳細を閉じる

    OBJECTIVE: Drug-eluting stent-induced coronary hyperconstricting responses remain an important issue. The adventitia harbors a variety of components that potently modulate vascular tone, including sympathetic nerve fibers (SNF) and vasa vasorum. Catheter-based renal denervation (RDN) inhibits sympathetic nerve activity. We, thus, examined whether RDN suppresses drug-eluting stent-induced coronary hyperconstricting responses, and if so, what mechanisms are involved. APPROACH AND RESULTS: Protocol 1: pigs implanted with everolimus-eluting stents into the left coronary arteries underwent coronary angiography at 1 month after implantation for assessment of coronary vasomotion and adventitial SNF formation. Drug-eluting stent-induced coronary hyperconstricting responses were significantly enhanced associated with enhanced coronary adventitial SNF and vasa vasorum formation. Protocol 2: pigs implanted with everolimus-eluting stents were randomly assigned to the RDN or sham group. The RDN group underwent renal ablation. At 1 month, RDN significantly caused marked damage of the SNF at the renal arteries without any stenosis, thrombus, or dissections. Notably, RDN significantly upregulated the expression of α2-adrenergic receptor-binding sites in the nucleus tractus solitarius, attenuated muscle sympathetic nerve activity, and decreased systolic blood pressure and plasma renin activity. In addition, RDN attenuated coronary hyperconstricting responses to intracoronary serotonin at the proximal and distal stent edges associated with decreases in SNF and vasa vasorum formation, inflammatory cell infiltration, and Rho-kinase expression/activation. Furthermore, there were significant positive correlations between SNF and vasa vasorum and between SNF and coronary vasoconstricting responses. CONCLUSIONS: These results provide the first evidence that RDN ameliorates drug-eluting stent-induced coronary hyperconstricting responses in pigs in vivo through the kidney-brain-heart axis.

  14. ラットPETを用いたヒト内部被曝線量の非侵襲的推定手法の検討

    志田原 美保, 猪又 嵩斗, 小山 千莉, 船木 善仁, 田代 学, 古本 祥三, 谷内 一彦, 権田 幸祐, 渡部 浩司

    核医学 54 (Suppl.) S199-S199 2017年9月

    出版者・発行元:(一社)日本核医学会

    ISSN:0022-7854

    eISSN:2189-9932

  15. Association of Coronary Perivascular Adipose Tissue Inflammation and Drug-Eluting Stent-Induced Coronary Hyperconstricting Responses in Pigs: 18F-Fluorodeoxyglucose Positron Emission Tomography Imaging Study. 国際誌 査読有り

    Kazuma Ohyama, Yasuharu Matsumoto, Hirokazu Amamizu, Hironori Uzuka, Kensuke Nishimiya, Susumu Morosawa, Michinori Hirano, Hiroshi Watabe, Yoshihito Funaki, Satoshi Miyata, Jun Takahashi, Kenta Ito, Hiroaki Shimokawa

    Arteriosclerosis, thrombosis, and vascular biology 37 (9) 1757-1764 2017年9月

    DOI: 10.1161/ATVBAHA.117.309843  

    ISSN:1079-5642

    詳細を見る 詳細を閉じる

    OBJECTIVE: Although coronary perivascular adipose tissue (PVAT) may play important roles as a source of inflammation, the association of coronary PVAT inflammation and coronary hyperconstricting responses remains to be examined. We addressed this important issue in a porcine model of coronary hyperconstricting responses after drug-eluting stent implantation with 18F-fluorodeoxyglucose (18F-FDG) positron emission tomographic imaging. APPROACH AND RESULTS: An everolimus-eluting stent (EES) was randomly implanted in pigs into the left anterior descending or the left circumflex coronary artery while nonstented coronary artery was used as a control. After 1 month, coronary vasoconstricting responses to intracoronary serotonin (10 and 100 μg/kg) were examined by coronary angiography in vivo, followed by in vivo and ex vivo 18F-FDG positron emission tomographic/computed tomographic imaging. Coronary vasoconstricting responses to serotonin were significantly enhanced at the EES edges compared with the control site (P<0.01; n=40). Notably, in vivo and ex vivo 18F-FDG positron emission tomographic/computed tomographic imaging and autoradiography showed enhanced 18F-FDG uptake and its accumulation in PVAT at the EES edges compared with the control site, respectively (both P<0.05). Furthermore, histological and reverse transcription polymerase chain reaction analysis showed that inflammatory changes of coronary PVAT were significantly enhanced at the EES edges compared with the control site (all P<0.01). Importantly, Rho-kinase expressions (ROCK1/ROCK2) and Rho-kinase activity (phosphorylated myosin phosphatase target subunit-1) at the EES edges were significantly enhanced compared with the control site. CONCLUSIONS: These results indicate for the first time that inflammatory changes of coronary PVAT are associated with drug-eluting stent-induced coronary hyperconstricting responses in pigs in vivo and that 18F-FDG positron emission tomographic imaging is useful for assessment of coronary PVAT inflammation.

  16. In vivo visualization of tau deposits in corticobasal syndrome by F-18-THK5351 PET 査読有り

    Akio Kikuchi, Nobuyuki Okamura, Takafumi Hasegawa, Ryuichi Harada, Shoichi Watanuki, Yoshihito Funaki, Kotaro Hiraoka, Toru Baba, Naoto Sugeno, Ryuji Oshima, Shun Yoshida, Junpei Kobayashi, Michinori Ezura, Michiko Kobayashi, Ohito Tano, Shunji Mugikura, Ren Iwata, Aiko Ishiki, Katsutoshi Furukawa, Hiroyuki Arai, Shozo Furumoto, Manabu Tashiro, Kazuhiko Yanai, Yukitsuka Kudo, Atsushi Takeda, Masashi Aoki

    NEUROLOGY 87 (22) 2309-2316 2016年11月

    出版者・発行元:LIPPINCOTT WILLIAMS & WILKINS

    DOI: 10.1212/WNL.0000000000003375  

    ISSN:0028-3878

    eISSN:1526-632X

    詳細を見る 詳細を閉じる

    Objective: To determine whether F-18-THK5351 PET can be used to visualize tau deposits in brain lesions in live patients with corticobasal syndrome (CBS). Methods: We evaluated the in vitro binding of H-3-THK5351 in postmortem brain tissues from a patient with corticobasal degeneration (CBD). In clinical PET studies, F-18-THK5351 retention in 5 patients with CBS was compared to that in 8 age-matched normal controls and 8 patients with Alzheimer disease (AD). Results: H-3-THK5351 was able to bind to tau deposits in the postmortem brain with CBD. In clinical PET studies, the 5 patients with CBS showed significantly higher F-18-THK5351 retention in the frontal, parietal, and globus pallidus than the 8 age-matched normal controls and patients with AD. Higher F-18-THK5351 retention was observed contralaterally to the side associated with greater cortical dysfunction and parkinsonism. Conclusions: F-18-THK5351 PET demonstrated high tracer signal in sites susceptible to tau deposition in patients with CBS. F-18-THK5351 should be considered as a promising candidate radio-tracer for the in vivo imaging of tau deposits in CBS.

  17. F-18-THK5351: A Novel PET Radiotracer for Imaging Neurofibrillary Pathology in Alzheimer Disease 査読有り

    Ryuichi Harada, Nobuyuki Okamura, Shozo Furumoto, Katsutoshi Furukawa, Aiko Ishiki, Naoki Tomita, Tetsuro Tago, Kotaro Hiraoka, Shoichi Watanuki, Miho Shidahara, Masayasu Miyake, Yoichi Ishikawa, Rin Matsuda, Akie Inami, Takeo Yoshikawa, Yoshihito Funaki, Ren Iwata, Manabu Tashiro, Kazuhiko Yanai, Hiroyuki Arai, Yukitsuka Kudo

    JOURNAL OF NUCLEAR MEDICINE 57 (2) 208-214 2016年2月

    出版者・発行元:SOC NUCLEAR MEDICINE INC

    DOI: 10.2967/jnumed.115.164848  

    ISSN:0161-5505

    eISSN:1535-5667

    詳細を見る 詳細を閉じる

    Imaging of neurofibrillary pathology in the brain helps in diagnosing dementia, tracking disease progression, and evaluating the therapeutic efficacy of antidementia drugs. The radiotracers used in this imaging must be highly sensitive and specific for tau protein fibrils in the human brain. We developed a novel-tau PET tracer, F-18-THK5351, through compound optimization of arylquinoline derivatives. Methods: The in vitro binding properties, pharmacokinetics, and safety of F-18-THK5351 were investigated, and a clinical study on Alzheimer disease (AD) patients was performed. Results: F-18-THK5351 demonstrated higher binding affinity for hippocampal homogenates from AD brains and faster dissociation from white matter tissue than did F-18-THK5117. The THK5351 binding amount correlated with the amount of tau deposits in human brain samples. Autoradiography of brain sections revealed that THK5351 bound to neurofibrillary tangles selectively and with a higher signal-to background ratio than did THK5117. THK5351 exhibited favorable pharmacokinetics and no defluorination in mice. In first-in-human PET studies in AD patients, F-18-THK5351 demonstrated faster kinetics, higher contrast, and lower retention in subcortical white matter than F-18-THK5117. Conclusion: F-18-THK5351 is a useful PET tracer for the early detection of neurofibrillary pathology in AD patients.

  18. Histamine H-1 receptor occupancy by the new-generation antipsychotics olanzapine and quetiapine: a positron emission tomography study in healthy volunteers 査読有り

    Hirotoshi Sato, Chihiro Ito, Kotaro Hiraoka, Manabu Tashiro, Katsuhiko Shibuya, Yoshihito Funaki, Takeo Yoshikawa, Ren Iwata, Hiroo Matsuoka, Kazuhiko Yanai

    PSYCHOPHARMACOLOGY 232 (19) 3497-3505 2015年10月

    出版者・発行元:SPRINGER

    DOI: 10.1007/s00213-015-4002-2  

    ISSN:0033-3158

    eISSN:1432-2072

    詳細を見る 詳細を閉じる

    Rationale Histamine H-1 antagonists have hypnotic, appetite-promoting, and sedative side effects. Most second-generation antipsychotics have potent antagonistic effects on histamine H-1 receptor (H1R). Positron emission tomography (PET) can measure the H1R occupancy (H1RO) in vivo, although there are no reports regarding antipsychotics. Objectives We studied the H1RO of olanzapine and quetiapine in vivo with respect to their plasma concentrations and subjective drowsiness by performing human PET imaging studies with [C-11]doxepin, a potent PET ligand of H1R. Methods Six healthy Japanese male volunteers were enrolled. Cross-randomized PET imaging was performed after a single oral administration of olanzapine (2.5 mg), quetiapine (25mg), or placebo. PET data were analyzed by region of interest and voxel-by-voxel analysis. We concurrently measured plasma drug concentrations by liquid chromatography/tandem mass spectrometry and evaluated subjective sleepiness. Results The binding potential ratios of olanzapine and quetiapine in the cerebral cortex were significantly lower than that of the placebo. The H1RO values of olanzapine and quetiapine in the cortex were approximately 61-80 and 56-81 %, respectively. The binding potential ratios of the drugs were significantly lower than that of the placebo in the dorsolateral prefrontal and lateral temporal cortices, and anterior and posterior cingulate gyri. The H1RO values in the cortex were significantly correlated with subjective sleepiness but not plasma drug concentrations. Conclusions Olanzapine and quetiapine have high H1RO values in the human brain under their clinical minimum doses. This study provides a foundation of the properties by which new-generation antipsychotics block the central histaminergic system in humans.

  19. Longitudinal Assessment of Tau Pathology in Patients with Alzheimer's Disease Using [F-18] THK-5117 Positron Emission Tomography 査読有り

    Aiko Ishiki, Nobuyuki Okamura, Katsutoshi Furukawa, Shozo Furumoto, Ryuichi Harada, Naoki Tomita, Kotaro Hiraoka, Shoichi Watanuki, Yoichi Ishikawa, Tetsuro Tago, Yoshihito Funaki, Ren Iwata, Manabu Tashiro, Kazuhiko Yanai, Yukitsuka Kudo, Hiroyuki Arai

    PLOS ONE 10 (10) e0140311 2015年10月

    出版者・発行元:PUBLIC LIBRARY SCIENCE

    DOI: 10.1371/journal.pone.0140311  

    ISSN:1932-6203

    詳細を見る 詳細を閉じる

    The formation of neurofibrillary tangles is believed to contribute to the neurodegeneration observed in Alzheimer's disease (AD). Postmortem studies have shown strong associations between the neurofibrillary pathology and both neuronal loss and the severity of cognitive impairment. However, the temporal changes in the neurofibrillary pathology and its association with the progression of the disease are not well understood. Tau positron emission tomography (PET) imaging is expected to be useful for the longitudinal assessment of neurofibrillary pathology in the living brain. Here, we performed a longitudinal PET study using the tau-selective PET tracer [F-18] THK-5117 in patients with AD and in healthy control subjects. Annual changes in [F-18] THK-5117 binding were significantly elevated in the middle and inferior temporal gyri and in the fusiform gyrus of patients with AD. Compared to patients with mild AD, patients with moderate AD showed greater changes in the tau load that were more widely distributed across the cortical regions. Furthermore, a significant correlation was observed between the annual changes in cognitive decline and regional [F-18] THK-5117 binding. These results suggest that the cognitive decline observed in patients with AD is attributable to the progression of neurofibrillary pathology. Longitudinal assessment of tau pathology will contribute to the assessment of disease progression and treatment efficacy.

  20. Quantitative kinetic analysis of PET amyloid imaging agents [C-11]BF227 and [F-18]FACT in human brain 査読有り

    Miho Shidahara, Hiroshi Watabe, Manabu Tashiro, Nobuyuki Okamura, Shozo Furumoto, Shoichi Watanuki, Katsutoshi Furukawa, Yuma Arakawa, Yoshihito Funaki, Ren Iwata, Kohsuke Gonda, Yukitsuka Kudo, Hiroyuki Arai, Kiichi Ishiwata, Kazuhiko Yanai

    NUCLEAR MEDICINE AND BIOLOGY 42 (9) 734-744 2015年9月

    出版者・発行元:ELSEVIER SCIENCE INC

    DOI: 10.1016/j.nucmedbio.2015.05.001  

    ISSN:0969-8051

    eISSN:1872-9614

    詳細を見る 詳細を閉じる

    Introduction: The purpose of this study was to compare two amyloid imaging agents, [C-11]BF227 and [F-18]FACT (derivative from [C-11]BF227) through quantitative pharmacokinetics analysis in human brain. Methods: Positron emission tomography studies were performed on six elderly healthy control (HC) subjects and seven probable Alzheimer's disease (AD) patients with [C-11]BF227 and 10 HC subjects and 10 probable AD patients with [F-18]FACT. Data from nine regions of interest were analyzed by several approaches, namely non-linear least-squared fitting methods with arterial input functions (one-tissue compartment model(1TCM), two-tissue compartment model (2TCM)), Logan plot, and linearized methods with reference region (Reference Logan plot (RefLogan), MRTM0, MRTM2). We also evaluated SUV and SUVR for both tracers. The parameters estimated by several approaches were compared between two tracers for detectability of differences between HC and AD patients. Results: For [C-11]BF227, there were no significant difference of V-T (2TCM, 1TCM) and SUV in all regions (Student t-test; p &lt; 0.05) and significant differences in the DVRs (Logan, RefLogan, and MRTM2) and SUVRs in six neocortical regions (p &lt; 0.05) between the HC and AD groups. For [F-18]FACT, significant differences in DVRs (RefLogan, MRTM0, and MRTM2) were observed in more than four neocortical regions between the HC and AD groups (p &lt; 0.05), and the significant differences were found in SUVRs for two neocortical regions (inferior frontal coretex and lateral temporal coretex). Our results showed that both tracers can clearly distinguish between HC and AD groups although the pharmacokinetics and distribution patterns in brain for two tracers were substantially different. Conclusion: This study revealed that although the PET amyloid imaging agents [C-11]BF227 and [F-18]FACT have similar chemical and biological properties, they have different pharmacokinetics, and caution must be paid for usage of the tracers. (C) 2015 Elsevier Inc. All rights reserved.

  21. [18F]THK-5117 PET for assessing neurofibrillary pathology in Alzheimer’s disease 査読有り

    Harada R, Okamura N, Furumoto S, Furukawa K, Ishiki K, Tomita N, Hiraoka K, Watanuki S, Shidahara M, Miyake M, Ishikawa Y, Matsuda R, Inami A, Yoshikawa T, Tago T, Funaki Y

    Eur. J. Nucl. Med. Mol. Imaging. 42 (7) 1052-1061 2015年6月

    出版者・発行元:None

    DOI: 10.1007/s00259-015-3035-4  

    ISSN:1619-7070

    eISSN:1619-7089

  22. CONCENTRATION OF CISPLATIN-INCORPORATED POLYMERIC MICELLES IN A MURINE SOLID TUMOR EVALUATED USING PIXE ANALYSIS

    A. TERAKAWA, K. ISHII, S. MATSUYAMA, Y. KIKUCHI, T. KAWAMURA, Y. TAKAHASHI, Y. MIURA, M. KARAHASHI, K. KUSANO, H. YAMAZAKI, Y. FUNAKI, K. MIZUNO, N. ITO, S. WADA, K. SERA

    International Journal of PIXE Vol. 24 (Nos. 1 & 2) 37-43 2014年

    DOI: 10.1142/S0129083514500053  

  23. Effects of a vascular disrupting agent for cancer treatment on normal tissue evaluated by PIXE analysis using quantum dots 査読有り

    A. Terakawa, K. Ishii, S. Matsuyama, Y. Kikuchi, K. Kusano, M. Karahashi, Y. Nozawa, S. Yamauchi, K. Kikuchi, S. Furumoto, Y. Funaki, N. Ito, S. Wada, K. Sera

    International Journal of PIXE Vol. 24 (Nos. 1 & 2) 59-65 2014年

    DOI: 10.1142/S0129083514500077  

  24. Histamine H(1) receptor occupancy by the new-generation antidepressants fluvoxamine and mirtazapine: a positron emission tomography study in healthy volunteers. 国際誌 査読有り

    Sato H, Ito C, Tashiro M, Hiraoka K, Shibuya K, Funaki Y, Iwata R, Matsuoka H, Yanai K

    Psychopharmacology 230 (2) 227-234 2013年6月1日

    DOI: 10.1007/s00213-013-3146-1  

  25. Adsorption and separation behavior of yttrium and strontium in nitric acid solution by extraction chromatography using a macroporous silica-based adsorbent 査読有り

    Yuanlai Xu, Seong-Yun Kim, Tatsuya Ito, Kasane Nakazawa, Yoshihito Funaki, Tsutomu Tada, Keitaro Hitomi, Keizo Ishii

    JOURNAL OF CHROMATOGRAPHY A 1263 28-33 2012年11月

    出版者・発行元:ELSEVIER SCIENCE BV

    DOI: 10.1016/j.chroma.2012.09.036  

    ISSN:0021-9673

    詳細を見る 詳細を閉じる

    To separate Y-90 from the fission product Sr-90-Y-90 group, a silica-based TODGA/SiO2-P adsorbent was prepared by impregnating N,N,N',N'-tetraoctyl-3-oxapentane-1,5-diamide (TODGA) extractant into the macroporous SiO2-P support with a mean diameter of 60 mu m. The adsorption behavior of Sr(II) and Y(III) onto TODGA/SiO2-P adsorbent from HNO3 solution and their mutual separation were investigated. Under the experimental conditions, this adsorbent showed high adsorption affinity to Y(III) and weak adsorption to Sr(II). It was found that the adsorption process of Y(III) could be expressed by both of Langmuir monomolecular layer adsorption mode and the pseudo-second order model. From the results of stability experiments, it became clear that TODGA/SiO2-P adsorbent is stable in 3 M HNO3 solution for 1 month contact time at 298 K. Using a column packed with TODGA/SiO2-P adsorbent, Sr(II) and Y(III) were eluted by distilled water and diethylenetriamine pentaacetic acid (DTPA) solution, respectively. The separation of Y(III) from Sr(II)-Y(III) group was achieved successfully. (C) 2012 Elsevier B.V. All rights reserved.

  26. [ 11C]doxepin binding to histamine H1 receptors in living human brain: Reproducibility during attentive waking and circadian rhythm 査読有り

    Katsuhiko Shibuya, Yoshihito Funaki, Kotaro Hiraoka, Takeo Yoshikawa, Fumito Naganuma, Masayasu Miyake, Shoichi Watanuki, Hirotoshi Sato, Manabu Tashiro, Kazuhiko Yanai

    Frontiers in Systems Neuroscience 6 (2012) 1-7 2012年6月11日

    DOI: 10.3389/fnsys.2012.00045  

    ISSN:1662-5137

    詳細を見る 詳細を閉じる

    Molecular imaging in neuroscience is a new research field that enables visualization of the impact of molecular events on brain structure and function in humans. While magnetic resonance-based imaging techniques can provide complex information at the level of system, positron emission tomography (PET) enables determination of the distribution and density of receptor and enzyme in the human brain. Previous studies using [ 11C]raclopride and [ 11C]FLB457 revealed that the release of neuronal dopamine was increased in human brain by psychostimulants or reward stimuli. Following on from these previous [ 11C]raclopride studies, we examined whether the levels of neuronal release of histamine might change [ 11C]doxepin binding to the H1 receptors under the influence of physiological stimuli. The purpose of the present study was to evaluate the test-retest reliability of quantitative measurement of [ 11C]doxepin binding between morning and afternoon and between resting and attentive waking conditions in healthy human subjects. There was a trend for a decrease in [ 11C]doxepin binding during attentive calculation tasks compared with that in resting conditions, but the difference (less than 10%) was not significant. Similarly, the binding potential of [ 11C]doxepin in the cerebral cortex was slightly higher in the morning than that in the afternoon, but it was also insignificant. These data suggest that higher histamine release during wakefulness could not decrease the [ 11C]doxepin binding in the brain. This study confirmed the reproducibility and reliability of [ 11C]doxepin in the previous imaging studies to measure the H1 receptor. © 2012 Shibuya,Funaki, Hiraoka, Yoshikawa, Naganuma, Miyake, Watanuki, Sato, Tashiroand Yanai.

  27. Cholinergic Deficit and Response to Donepezil Therapy in Parkinson's Disease with Dementia: [5-11C-Methoxy]donepezil-PET Study 査読有り

    Kotaro Hiraoka, Nobuyuki Okamura, Yoshihito Funaki, Akiko Hayashi, Manabu Tashiro, Kinya Hisanaga, Toshikatsu Fujii, Atsushi Takeda, Kazuhiko Yanai, Ren Iwata, Etsuro Mori

    NEUROLOGY 78 (3) 137-143 2012年4月

    出版者・発行元:LIPPINCOTT WILLIAMS & WILKINS

    DOI: 10.1159/000338774  

    ISSN:0028-3878

  28. Cholinergic Deficit and Response to Donepezil Therapy in Parkinson's Disease with Dementia: [5-11C-Methoxy]donepezil-PET Study 査読有り

    Kotaro Hiraoka, Nobuyuki Okamura, Yoshihito Funaki, Akiko Hayashi, Manabu Tashiro, Kinya Hisanaga, Toshikatsu Fujii, Atsushi Takeda, Kazuhiko Yanai, Ren Iwata, Etsuro Mori

    NEUROLOGY 78 (1) 2012年4月

    出版者・発行元:LIPPINCOTT WILLIAMS & WILKINS

    ISSN:0028-3878

  29. Greater Responsiveness to Donepezil in Alzheimer Patients With Higher Levels of Acetylcholinesterase Based on Attention Task Scores and a Donepezil PET Study 査読有り

    Masashi Kasuya, Kenichi Meguro, Nobuyuki Okamura, Yoshihito Funaki, Hiroyasu Ishikawa, Naofumi Tanaka, Ren Iwata, Kazuhiko Yanai

    ALZHEIMER DISEASE & ASSOCIATED DISORDERS 26 (2) 113-118 2012年4月

    出版者・発行元:LIPPINCOTT WILLIAMS & WILKINS

    DOI: 10.1097/WAD.0b013e3182222bc0  

    ISSN:0893-0341

    詳細を見る 詳細を閉じる

    The aim of the study was to predict donepezil responders among patients with Alzheimer disease (AD) based on cognitive tests and positron emission tomography. The Mini-Mental State Examination, Digit Symbol subtest (DigSm) of Wechsler Adult Intelligence Scale Revised, and Trail-Making Test A were administered for 80 patients with AD to assess global function, attention, and executive function, respectively. The same tests and the Clinical Global Impression (CGI) scale were conducted after treatment with oral donepezil (5 mg/d) for 6 months (study 1). [C-11]-Donepezil positron emission tomography examinations were conducted before and after treatment for 30 randomly selected patients. The distribution volume (DV), which indicates the density of donepezil-binding sites, was calculated using Logan graphical analysis (study 2). In study 1, 35 patients were identified as responders based on the CGI and Mini-Mental State Examination changes. These patients had higher baseline DigSm scores compared with nonresponders. In study 2, 15 patients were responders. DigSm correlated with DV at baseline. DV at baseline and %DV change in responders were higher than in nonresponders, and these variables correlated with Delta DigSm and CGI scores. Higher baseline attention may predict responsiveness to donepezil in patients with AD, and higher acetylcholinesterase levels result in a greater clinical effect.

  30. Influence of loading on bone metabolism around dental implants in rat tibia 査読有り

    Miou Yamamoto, Masayoshi Yokoyama, Shigeto Koyama, Hiroto Sasaki, Yoshihito Funaki, Youhei Kikuchi, Hiromichi Yamazaki, Keizo Ishii, Keiichi Sasaki

    Interface Oral Health Science 2011 362-364 2012年1月1日

    出版者・発行元:Springer Japan

    DOI: 10.1007/978-4-431-54070-0_105  

    詳細を見る 詳細を閉じる

    This article reviewed the bone metabolic activity around titanium implants in rat tibia under the mechanical loading condition on the implant.

  31. Cholinergic Deficit and Response to Donepezil Therapy in Parkinson's Disease with Dementia 査読有り

    Kotaro Hiraoka, Nobuyuki Okamura, Yoshihito Funaki, Akiko Hayashi, Manabu Tashiro, Kinya Hisanaga, Toshikatsu Fujii, Atsushi Takeda, Kazuhiko Yanai, Ren Iwata, Etsuro Mori

    EUROPEAN NEUROLOGY 68 (3) 137-143 2012年

    出版者・発行元:KARGER

    DOI: 10.1159/000338774  

    ISSN:0014-3022

    詳細を見る 詳細を閉じる

    Background: Although donepezil, an acetylcholinesterase inhibitor, has been proved to be effective in ameliorating cognitive impairment in Parkinson's disease with dementia (PDD), the responsiveness of patients to donepezil therapy varies. [5-C-11-methoxy] donepezil, the radiolabeled form of donepezil, is a ligand for positron emission tomography (PET), which can be exploited for the quantitative analysis of donepezil binding to acetylcholinesterase and for cholinergic imaging. Objectives: To investigate the deficits of the cholinergic system in the brain in PDD and its association with response to donepezil therapy. Methods: Twelve patients with PDD and 13 normal control subjects underwent [5-C-11-methoxy] donepezil-PET imaging. For patients with PDD, daily administration of donepezil was started after [5-C-11-methoxy] donepezil-PET imaging and continued for 3 months. Results: In the PDD group, the mean total distribution volume of the cerebral cortices was 22.7% lower than that of the normal control group. The mean total distribution volume of the patients with PDD was significantly correlated with improvement of visuoperceptual function after 3 months of donepezil therapy. Conclusion: The results suggest that donepezil therapy is more effective in patients with less decrease in acetylcholinesterase, a binding site of donepezil, at least in the specific cognitive domain. Copyright (C) 2012 S. Karger AG, Basel

  32. The relationship between the amount of [C-11]donepezil binding to brain acetylcholine esterase and the treatment efficacy of donepezil hydrochloride in the patients with Alzheimer's disease 査読有り

    Nobuyuki Okamura, Masashi Kasuya, Hiroyasu Ishikawa, Naofumi Tanaka, Yoshihito Funaki, Ren Iwata, Kenichi Meguro, Kazuhiko Yanai

    JOURNAL OF PHARMACOLOGICAL SCIENCES 118 (1) 108P-108P 2012年

    出版者・発行元:JAPANESE PHARMACOLOGICAL SOC

    ISSN:1347-8613

  33. In vivo evaluation of sedative properties of levocetirizine by small animal PET/CT 査読有り

    Tomomitsu Iida, Yoshihito Funaki, Kiichi Ishiwata, Fumito Naganuma, Ryuichi Harada, Ren Iwata, Kazuhiko Yanai

    JOURNAL OF PHARMACOLOGICAL SCIENCES 118 (1) 252P-252P 2012年

    出版者・発行元:JAPANESE PHARMACOLOGICAL SOC

    ISSN:1347-8613

  34. Quantitative analysis of amyloid β deposition in patients with Alzheimer's disease using positron emission tomography

    Manabu Tashiro, Nobuyuki Okamura, Shoichi Watanuki, Shozo Furumoto, Shozo Furumoto, Katsutoshi Furukawa, Yoshihito Funaki, Ren Iwata, Yukitsuka Kudo, Hiroyuki Arai, Hiroshi Watabe, Kazuhiko Yanai, Kazuhiko Yanai

    Early Detection and Rehabilitation Technologies for Dementia: Neuroscience and Biomedical Applications 220-230 2011年12月1日

    DOI: 10.4018/978-1-60960-559-9.ch029  

    詳細を見る 詳細を閉じる

    Positron emission tomography (PET) is a sensitive technique for functional and molecular imaging. In Japan, the incidence of cognitive disorders is increasing at an accelerated pace, partly due to the increasing size of the elderly population. Basic and clinical studies on dementia have become very important. In vivo detection of amyloid beta (Aβ) deposits could be useful for early diagnosis of Alzheimer&#039;s disease (AD). &quot;Aβ imaging&quot; by PET has been recognized as one of the most important methods for the early diagnosis of AD. Clinical PET studies have been conducted using several probes, such as [ 18 F]FDDNP, [ 11 C]SB-13 and [ 11 C]Pittsburgh compound-B ([ 11 C]PIB). [ 11 C]PIB is the most commonly used probe. In this chapter, a novel imaging probe, 2-[2-(2-dimethylaminothiazol-5-yl)-ethenyl] -6- [2-(fluoro)ethoxy] benzoxazole ([ 11 C]BF-227), is reported. To the authors&#039; knowledge, [ 11 C]BF-227 is the first Aβ imaging probe to be used in Japan. The purpose of this chapter is to examine methods for quantitative analysis of Aβ deposition in the human brain using PET and [ 11 C]BF-227. Six AD patients and six healthy control subjects were used in the present study. Dynamic PET images were obtained over 60 min. Blood samples were obtained from the radial arteries. The results were analyzed using Logan graphical analysis and full kinetic analysis. A significantly higher distribution volume ratio (DVR) value was observed in AD patients in cortical regions, e.g., the cingulate, frontal, temporal, parietal and occipital regions, than in control subjects. Satisfactory correlation of these values to the semiquantitative standardized uptake values (SUV) was obtained. These findings suggest that [ 11 C]BF-227 is a promising PET probe for clinical evaluation of early Aβ deposition in AD patients. © 2011, IGI Global.

  35. 頭頸部癌遺伝子治療に向けたナノバブルと超音波によるNIS遺伝子導入と124I-PETイメージング

    渡邊 夕紀子, 森 士朗, 堀江 佐知子, サックス・ニコラ, 李 麗, 李 深偉, 柳下 陽子, 高地 崇, 船木 善仁, 菊池 洋平, 山崎 浩道, 石井 慶造, 阪本 真弥, 宮下 仁, 小玉 哲也

    頭頸部癌 37 (2) 234-234 2011年5月

    出版者・発行元:(一社)日本頭頸部癌学会

    ISSN:1349-5747

    eISSN:1881-8382

  36. PIXE analysis of a murine solid tumor treated with proton therapy combined with cisplatin 査読有り

    A. Terakawa, K. Ishii, H. Yamazaki, S. Matsuyama, Y. Kikuchi, Y. Ito, A. Tagawa, S. Yasunaga, T. Kawamura, Y. Takahashi, Y. Hatori, N. Hamada, K. Fujiki, N. Ito, S. Wada, Y. Funaki, K. Sera

    X-RAY SPECTROMETRY 40 (3) 198-201 2011年5月

    出版者・発行元:WILEY-BLACKWELL

    DOI: 10.1002/xrs.1338  

    ISSN:0049-8246

    詳細を見る 詳細を閉じる

    Platinum concentration in a murine solid tumor treated with proton therapy combined with the platinum-based chemotherapeutic agent cisplatin [cis-diamminedichloro-platinum(II) (CDDP)] was investigated with conventional and submilli-PIXE (particle-induced X-ray emission) analyses. An enhanced therapeutic effect on tumor growth was observed in NFSa fibrosarcoma tumors in mice when proton therapy with a single dose of 30 Gy and CDDP treatment (10 mg/kg) were combined. The conventional PIXE analysis based on an internal standard method showed that the platinum concentration was 2.6 +/- 0.3 mu g/g for the tumor samples excised from the mice 6 h after the CDDP administration. The submilli-PIXE analysis of the tumor sections showed that spatial distribution of CDDP may be more or less uniform in the tumor. Copyright (C) 2011 John Wiley & Sons, Ltd.

  37. Donepezil Binding to Acetylcholinesterase and Response to Donepezil Therapy in Parkinson’s Disease Dementia: [5-11C-methoxy]Donepezil-PET Study

    Hiraoka K, Okamura N, Funaki Y, Hayashi A, Tashiro M, Hisanaga K, Fujii T, A Takeda, Yanai K, Iwata R, Mori E

    CYRIC Annual Report 2010 106-109 2011年

    出版者・発行元:Cyclotron and Radioisotope Center, Tohoku University

    詳細を見る 詳細を閉じる

    CYRIC Annual Report 2010/2011

  38. In vivo pharmacological imaging study using small animal PET/CT 査読有り

    Katsuhiko Shibuya, Syozo Hurumoto, Yoshihito Funaki, Nobuyuki Okamura, Ryo Shinbo, Yoichi Ishikawa, Manabu Tashiro, Ren Iwata, Kazuhiko Yanai

    JOURNAL OF PHARMACOLOGICAL SCIENCES 115 (1) 229P-229P 2011年

    出版者・発行元:JAPANESE PHARMACOLOGICAL SOC

    ISSN:1347-8613

  39. Next-Day Residual Sedative Effect After Nighttime Administration of an Over-the-Counter Antihistamine Sleep Aid, Diphenhydramine, Measured by Positron Emission Tomography 査読有り

    Dongying Zhang, Manabu Tashiro, Katsuhiko Shibuya, Nobuyuki Okamura, Yoshihito Funaki, Takeo Yoshikawa, Masato Kato, Kazuhiko Yanai

    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY 30 (6) 694-701 2010年12月

    出版者・発行元:LIPPINCOTT WILLIAMS & WILKINS

    DOI: 10.1097/JCP.0b013e3181fa8526  

    ISSN:0271-0749

    eISSN:1533-712X

    詳細を見る 詳細を閉じる

    Antihistamines often are self-administered at night as over-the-counter (OTC) sleep aids, but their next-day residual sedative effect has never been evaluated using a reliable quantitative method such as positron emission tomography (PET). We performed a double-blind, placebo-controlled, crossover study in which we evaluated the residual effect the next day after nighttime administration of diphenhydramine, a commonly used OTC sleep aid, in terms of brain H-1 receptor occupancy (H1RO) measured using C-11-doxepin-PET. We also compared the results of diphenhydramine with those of bepotastine, a second-generation antihistamine. Eight healthy adult male subjects underwent PET measurement the morning (11:00) after random oral administration of diphenhydramine (50 mg), bepotastine (10 mg), or placebo the night before (23:00). Binding potential ratios and H1ROs were calculated in different brain regions of interest such as the cingulate gyrus, frontotemporal cortex, and cerebellum. Subjective sleepiness and plasma drug concentration also were measured. Calculation of binding potential ratios revealed significantly lower values for diphenhydramine than for bepotastine or placebo in all regions of interest (P &lt; 0.01). Cortical mean H1RO after diphenhydramine treatment was 44.7% compared with 16.6% for bepotastine treatment (P &lt; 0.01). Subjective sleepiness was not significantly different among the subjects treated with each test drug or the placebo. In conclusion, the next-day residual sedative effect after nighttime administration of the OTC sleep aid diphenhydramine was verified for the first time by direct PET measurement of H1RO. Taking into account the possible hangover effect of OTC antihistamine sleep aids, care needs to be taken during their administration.

  40. Quantitative Analysis of amyloid beta deposition in the brain of Alzheimer&apos;s disease patients using PET and [11C]BF-227 査読有り

    M. Tashiro, N. Okamura, S. Watanuki, S. Furumoto, K. Furukawa, Y. Funaki, R. Iwata, Y. Kudo, H. Arai, K. Yanai

    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING 37 (2) S234-S234 2010年10月

    出版者・発行元:SPRINGER

    ISSN:1619-7070

  41. Pharmacokinetics of [F-18]FACT, a new F-18-labeled amyloid imaging agent, in the brain of Alzheimer&apos;s disease patients 査読有り

    M. Tashiro, N. Okamura, S. Watanuki, S. Furumoto, K. Furukawa, Y. Funaki, R. Iwata, Y. Kudo, H. Arai, K. Yanai

    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING 37 (2) S234-S234 2010年10月

    出版者・発行元:SPRINGER

    ISSN:1619-7070

  42. 新規アミロイドイメージング薬剤18F-FACTの動態解析

    田代学, 岡村信行, 古本祥三, 四月朔日聖一, 船木善仁, 岩田錬, 工藤幸司, 古川勝敏, 伊藤浩, 荒井啓行, 谷内一彦

    核医学 47 (3) 424-424 2010年9月

    出版者・発行元:(一社)日本核医学会

    ISSN:0022-7854

    eISSN:2189-9932

  43. αシヌクレイノパチーにおける[11C]BF-227 PET画像所見

    岡村信行, 菊池昭夫, 武田篤, 古本祥三, 田代学, 船木善仁, 工藤幸司, 岩田錬, 谷内一彦

    核医学 47 (3) 403-403 2010年9月

    出版者・発行元:(一社)日本核医学会

    ISSN:0022-7854

    eISSN:2189-9932

  44. [5-11C-methoxy]donepezil-PETによるアセチルコリンエステラーゼの定量解析

    平岡宏太良, 岡村信行, 船木善仁, 四月朔日聖一, 田代学, 谷内一彦, 渡部浩司

    核医学 47 (3) 389-389 2010年9月

    出版者・発行元:(一社)日本核医学会

    ISSN:0022-7854

    eISSN:2189-9932

  45. In vivo visualization of alpha-synuclein deposition by carbon-11-labelled 2-[2-(2-dimethylaminothiazol-5-yl)ethenyl]-6-[2-(fluoro)ethoxy]benzoxazole positron emission tomography in multiple system atrophy 査読有り

    Akio Kikuchi, Atsushi Takeda, Nobuyuki Okamura, Manabu Tashiro, Takafumi Hasegawa, Shozo Furumoto, Michiko Kobayashi, Naoto Sugeno, Toru Baba, Yasuo Miki, Fumiaki Mori, Koichi Wakabayashi, Yoshihito Funaki, Ren Iwata, Shoki Takahashi, Hiroshi Fukuda, Hiroyuki Arai, Yukitsuka Kudo, Kazuhiko Yanai, Yasuto Itoyama

    BRAIN 133 (Part 6) 1772-1778 2010年6月

    出版者・発行元:OXFORD UNIV PRESS

    DOI: 10.1093/brain/awq091  

    ISSN:0006-8950

    詳細を見る 詳細を閉じる

    The histopathological hallmark of multiple system atrophy is the appearance of intracellular inclusion bodies, named glial cytoplasmic inclusions, which are mainly composed of alpha-synuclein fibrils. In vivo visualization of alpha-synuclein deposition should be used for the diagnosis and assessment of therapy and severity of pathological progression in multiple system atrophy. Because 2-[2-(2-dimethylaminothiazol-5-yl)ethenyl]-6-[2-(fluoro)ethoxy] benzoxazole could stain alpha-synuclein-containing glial cytoplasmic inclusions in post-mortem brains, we compared the carbon-11-labelled 2-[2-(2-dimethylaminothiazol-5-yl)ethenyl]-6-[2-(fluoro)ethoxy] benzoxazole positron emission tomography findings of eight multiple system atrophy cases to those of age-matched normal controls. The positron emission tomography data demonstrated high distribution volumes in the subcortical white matter (uncorrected P &lt; 0.001), putamen and posterior cingulate cortex (uncorrected P &lt; 0.005), globus pallidus, primary motor cortex and anterior cingulate cortex (uncorrected P &lt; 0.01), and substantia nigra (uncorrected P &lt; 0.05) in multiple system atrophy cases compared to the normal controls. They were coincident with glial cytoplasmic inclusion-rich brain areas in multiple system atrophy and thus, carbon-11-labelled 2-[2-(2-dimethylaminothiazol-5-yl)ethenyl]-6-[2-(fluoro)ethoxy] benzoxazole positron emission tomography is a promising surrogate marker for monitoring intracellular alpha-synuclein deposition in living brains.

  46. Delivery of Na/I Symporter Gene into Skeletal Muscle Using Nanobubbles and Ultrasound: Visualization of Gene Expression by PET 査読有り

    Yukiko Watanabe, Sachiko Horie, Yoshihito Funaki, Youhei Kikuchi, Hiromichi Yamazaki, Keizo Ishii, Shiro Mori, Georges Vassaux, Tetsuya Kodama

    JOURNAL OF NUCLEAR MEDICINE 51 (6) 951-958 2010年6月

    出版者・発行元:SOC NUCLEAR MEDICINE INC

    DOI: 10.2967/jnumed.109.074443  

    ISSN:0161-5505

    eISSN:1535-5667

    詳細を見る 詳細を閉じる

    The development of nonviral gene delivery systems is essential in gene therapy, and the use of a minimally invasive imaging methodology can provide important clinical endpoints. In the current study, we present a new methodology for gene therapy-a delivery system using nanobubbles and ultrasound as a nonviral gene delivery method. We assessed whether the gene transfer allowed by this methodology was detectable by PET and bioluminescence imaging. Methods: Two kinds of reported vectors (luciferase and human Na/I symporter [hNIS]) were transfected or cotransfected into the skeletal muscles of normal mice (BALB/c) using the ultrasound-nanobubbles method. The kinetics of luciferase gene expression were analyzed in vivo using bioluminescence imaging. At the peak of gene transfer, PET of hNIS expression was performed using our recently developed PET scanner, after I-124 injection. The imaging data were confirmed using reverse-transcriptase polymerase chain reaction amplification, biodistribution, and a blocking study. The imaging potential of the 2 methodologies was evaluated in 2 mouse models of human pathology (McH/Ipr-RA1 mice showing vascular disease and C57BL/10-mdx Jic mice showing muscular dystrophy). Results: Peak luciferase gene activity was observed in the skeletal muscle 4 d after transfection. On day 2 after hNIS and luciferase cotransfection, the expression of these genes was confirmed by reverse-transcriptase polymerase chain reaction on a muscle biopsy. PET of the hNIS gene, biodistribution, the blocking study, and autoradiography were performed on day 4 after transfection, and it was indicated that hNIS expression was restricted to the site of plasmid administration (skeletal muscle). Similar localized PET and 124I accumulation were successfully obtained in the disease-model mice. Conclusion: The hNIS gene was delivered into the skeletal muscle of healthy and disease-model mice by the ultrasound-nanobubbles method, and gene expression was successfully visualized with PET. The combination of ultrasound-nanobubble gene transfer and PET may be applied to gene therapy clinical protocols.

  47. S0201-3-3 Fine PETによる骨代謝イメージング(骨再生と骨再建のためのバイオマテリアル(3),社会変革を技術で廻す機械工学)

    横山 政宣, 山本 未央, 船木 善仁, 菊池 洋平, 山崎 浩道, 石井 慶造, 佐々木 啓一

    年次大会講演論文集 2010 35-36 2010年

    出版者・発行元:一般社団法人日本機械学会

    DOI: 10.1299/jsmemecjo.2010.5.0_35  

    詳細を見る 詳細を閉じる

    This study aimed to examine the influence of early loading on dynamic changes of bone metabolism around dental implants by using a Fine PET. Two titanium implants were inserted in the right tibiae of Wistar rats. 1 day after insertion, closed coil springs with 4.0 N were applied to the implants. The rats with ^<18>F^- (5mCi/rat) intravenously-injected were scanned by PET scanner at 4, 7, 14, 28 days after load application. Round ROIs were set around the distal implant (right tibia) and at the intact side (left tibia). Longitudinal dynamic changes in bone metabolism were evaluated by examination of the accumulation count of ^<18>F^-at each ROI. The results shows that early loading to the implant initially enhanced the bone metabolism around the implant, however, metabolic activity returned to pre-loading level with time despite a static force being applied to the implants.

  48. Evaluation of bone metabolism of temporomandibular joint by using high resolution PET scanner 査読有り

    Miou Yamamoto, Masayoshi Yokoyama, Shigeto Koyama, Yoshihito Funaki, Youhei Kikuchi, Kenji Nakamura, Kouichi Nakazawa, Hiromichi Yamazaki, Keizo Ishii, Keiichi Sasaki

    INTERFACE ORAL HEALTH SCIENCE 2009 190-+ 2010年

    出版者・発行元:SPRINGER-VERLAG TOKYO

    DOI: 10.1007/978-4-431-99644-6_44  

    詳細を見る 詳細を閉じる

    Bone metabolism of temporomandibular joint (TMJ) induced by loss of unilateral occlusal support was evaluated using the high resolution positron emission tomography scanner. Highly enhanced metabolic activity of TMJ in the extracted side was observed in the early stage after tooth extraction, and it was gradually decreased.

  49. Quantitative Analysis of Amyloid Beta Deposition in the Brain of Alzheimer's Disease Patients Using PET and [C-11]BF-227 and [F-18]FACT 査読有り

    M. Tashiro, N. Okamura, S. Watanuki, S. Furumoto, K. Furukawa, Y. Funaki, K. Shibuya, R. Iwata, Y. Kudo, H. Arai, K. Yanai

    6TH WORLD CONGRESS OF BIOMECHANICS (WCB 2010), PTS 1-3 31 1648-+ 2010年

    出版者・発行元:SPRINGER

    ISSN:1680-0737

    詳細を見る 詳細を閉じる

    In vivo detection of amyloid deposits is useful for early diagnosis of Alzheimer's disease (AD) and for prediction of potential converters from mild cognitive impairment (MCI) to AD. Our original imaging probe, [C-11]BF-227, has been shown to be useful for clinical evaluation of AD, MCI and various neurodegenerative disorders using positron emission tomography (PET). Purpose of the present study is to examine methods for quantitative analysis of amyloid deposition in human brain using PET and [C-11]BF-227 as well as our newer compound [F-18]FACT. For [C-11]BF-227, six AD patients (mean age: 73.0 y.o.) and six healthy controls (mean age: 61.3 y.o.) were studied. For [F-18]FACT, ten AD patients (mean age: 74.5 y.o.) and six healthy controls (mean age: 68.3 y.o.) were studied in the present study. Regions of interest (ROIs) were placed on various cortical and subcortical regions in dynamic PET images of 60-min- and 90-min-long duration, based on the coregistered MRI T1 images. Results of quantification using arterial inputs were compared to those calculated by Logan graphical analysis with arterial data (LGA) and with the reference data (LGAR), and to those calculated by full kinetic analysis based on 1- and 2-tissue compartmental models (1TM and 2TM). These results were compared to the ratio of standardized uptake values (SUV) in the cortex to that in the cerebellum, as well. [C-11]BF-227 displayed significantly higher distribution volume ratio (DVR) values in AD patients than in controls in various cortical regions such as the cingulate, temporal and occipital regions, especially in the temporo-occipital regions. The preliminary results of quantitative analysis of [F-18]FACT showed nearly the same findings as those of [C-11]BF-227. Considering the longer half-life of F-18 nuclide (110 min) than that of C-11 nuclide (20 min), this tracer could be used as a diagnosing pharmaceutical for delivery.

  50. Quantitative Analysis of Donepezil Binding to Acetylcholinesterase using PET and [5-11C-methoxy]donepezil.

    Hiraoka K, Okamura N, Funaki Y, Watanuki S, Tashiro M, Kato M, Hayashi A, Hosokai Y, Yamasaki H, Fujii T, Mori E, Yanai K, Watabe H

    Proceedings of 13th International Symposium of Tohoku University Global COE Program Nano-Biomedical Engineering Education and Research Network Centre. 12-13 2010年

  51. Residual sedative effect of OTC antihistamines by measuring central H1 receptor (H1R) occupancy using C-11-doxepin-PET 査読有り

    Dongying Zhang, Manabu Tashiro, Yoshihito Funaki, Nobuyuki Okamura, Masato Kato, Kazuhiko Yanai

    JOURNAL OF PHARMACOLOGICAL SCIENCES 112 (1) 73P-73P 2010年

    出版者・発行元:JAPANESE PHARMACOLOGICAL SOC

    ISSN:1347-8613

  52. 前日に就寝前投与された抗ヒスタミン薬によるヒスタミンH1受容体占拠率の検討 ジフェンヒドラミンおよびベポタスチンの比較

    田代学, 張冬頴, 渋谷勝彦, 船木善仁, 岩田錬, 谷内一彦

    臨床薬理 40 (Suppl.) S275-S275 2009年11月

  53. Therapeutic efficacy of proton therapy combined with tumor blood flow interruption evaluated by high-resolution [18F]FDGPET A. Terakawa 査読有り

    K. Ishii, H. Yamazaki, Y. Funaki, M. Tashiro, S.Furumoto, S. Matsuyama, Y. Kikuchi, J. Arikawa, T. Togashi, W.Yamashita, H. Akiyama, K. Koyata, S. Wada, N. Itoh

    European Journal of Nuclear Medicine & Molecular Imaging 36 (sup2) S290 2009年10月

  54. Dose dependency of brain histamine H1 receptor occupancy following oral administration of cetirizine hydrochloride measured using PET with [C-11]doxepin 査読有り

    Manabu Tashiro, Motohisa Kato, Masayasu Miyake, Shoichi Watanuki, Yoshihito Funaki, Yoichi Ishikawa, Ren Iwata, Kazuhiko Yanai

    HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL 24 (7) 540-548 2009年10月

    出版者・発行元:WILEY-BLACKWELL

    DOI: 10.1002/hup.1051  

    ISSN:0885-6222

    eISSN:1099-1077

    詳細を見る 詳細を閉じる

    Aims The strength of sedation due to antihistamines can be evaluated using positron emission tomography (PET). The purpose of the present study is to measure histamine H-1 receptor (H1R) occupancy following oral administration of cetirizine (10 and 20 mg) in order to examine dose dependency. Methods Fifteen healthy male volunteers (age range, 20-35 years) were divided into 3 subgroups and were studied following single oral administration of cetirizine at 10 mg (n = 5) and 20 mg (n = 5) or hydroxyzine at 30 mg (n = 5) using PET with C-11-doxepin. Each subject was scanned also following the administration of placebo. Binding potential and H1RO values were calculated in the prefrontal and anterior cingulate cortices. Subjective sleepiness was also measured, and the correlation to H1RO was examined for each antihistamine. Results The averaged H1ROs of cetirizine 10 mg, 20 mg, and hydroxyzine 30 mg in the prefrontal and cingulate cortices was 12.6%, 25.2%, and 67.6%, respectively. The H1RO of hydroxyzine 30 mg correlated well with subjective sleepiness (p &lt; 0.001); however, those of cetirizine 10 and 20 mg showed no correlation with subjective sleepiness. Conclusion It was demonstrated that the brain penetration of orally administered cetirizine was dose-dependent. Cetirizine 10 mg, with its low H1RO and thus minimal sedation, could be more safely used than cetirizine 20 mg for the treatment of various allergic disorders. Copyright (c) 2009 John Wiley & Sons, Ltd.

  55. Comparison study of amyloid PET and voxel-based morphometry analysis in mild cognitive impairment and Alzheimer's disease 査読有り

    Masaaki Waragai, Nobuyuki Okamura, Katsutoshi Furukawa, Manabu Tashiro, Shozo Furumoto, Yoshihito Funaki, Motohisa Kato, Ren Iwata, Kazuhiko Yanai, Yukitsuka Kudo, Hiroyuki Arai

    JOURNAL OF THE NEUROLOGICAL SCIENCES 285 (1-2) 100-108 2009年10月

    出版者・発行元:ELSEVIER SCIENCE BV

    DOI: 10.1016/j.jns.2009.06.005  

    ISSN:0022-510X

    eISSN:1878-5883

    詳細を見る 詳細を閉じる

    Two techniques employed for the early diagnosis of dementia are the imaging of amyloid-beta protein using positron emission tomography (PET) and voxel-based morphometry analysis of MRI (VBM-MRI). The purpose of this study was-to evaluate the clinical utility of amyloid PET and VBM-MRI for the early diagnosis and tracking of the severity of Alzheimer's disease (AD). The neuritic plaque burden and gray matter losses were evaluated using [C-11]BF-227-PET and VBM-MRI in 12 healthy controls, 13 subjects with mild cognitive impairment (MCI), including 6 who converted to AD and 7 who did not convert, and 15 AD patients. The AD patients and the MCI converters exhibited a neocortical retention of BF-227 and parahippocampal gray matter loss shown by VBM-MRI. The MCI converters were more clearly distinguished from the MCI non-converters in BF-227-PET than VBM-MRI. The combined sample of the MCI converters and AD patients showed a significant correlation of MMSE scores with the global gray matter loss, but not with the BF-227 retention. These findings suggest that amyloid PET using [C-11]BF-227 is better suited for the prediction of conversion from MCI to AD, while VBM-MRI appears to be better suited for tracking the severity of dementia. (C) 2009 Elsevier B.V. All rights reserved.

  56. アルツハイマー病診断における[18F]FACT-PETの有用性の検討

    岡村信行, 古本祥三, 田代学, 古川勝敏, 杉健太郎, 船木善仁, 岩田錬, 荒井啓行, 工藤幸司, 谷内一彦

    核医学 46 (3) 319-319 2009年9月

    出版者・発行元:(一社)日本核医学会

    ISSN:0022-7854

    eISSN:2189-9932

  57. [11C]BF-227を用いた脳内アミロイド蓄積に関する動脈採血データを用いた定量解析

    田代学, 岡村信行, 熊谷和明, 古本祥三, 船木善仁, 木村裕一, 岩田錬, 工藤幸司, 渡部浩司, 荒井啓行, 谷内一彦

    核医学 46 (3) 262-262 2009年9月

    出版者・発行元:(一社)日本核医学会

    ISSN:0022-7854

    eISSN:2189-9932

  58. Assessment of new semiconductor animal PET performance in the rodent using [F-18]FDG, [C-11]raclopride, [C-11]doxepin and [C-11]donepezil 査読有り

    Y. Funaki, Y. Kikuchi, K. Nakazawa, H. Yamazaki, K. Ishii

    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING 36 (2) S415-S415 2009年9月

    出版者・発行元:SPRINGER

    ISSN:1619-7070

  59. Quantitative analysis of donepezil binding to acetylcholinesterase using positron emission tomography and [5-(11)C-methoxy]donepezil 査読有り

    Kotaro Hiraoka, Nobuyuki Okamura, Yoshihito Funaki, Shoichi Watanuki, Manabu Tashiro, Motohisa Kato, Akiko Hayashi, Yoshiyuki Hosokai, Hiroshi Yamasaki, Toshikatsu Fujii, Etsuro Mori, Kazuhiko Yanai, Hiroshi Watabe

    NEUROIMAGE 46 (3) 616-623 2009年7月

    出版者・発行元:ACADEMIC PRESS INC ELSEVIER SCIENCE

    DOI: 10.1016/j.neuroimage.2009.03.006  

    ISSN:1053-8119

    詳細を見る 詳細を閉じる

    The aim of this study was to establish kinetic analysis of [5-(11)C-methoxyldonepezil ([(11)C]donepezil), which was developed for the in-vivo visualization of donepezil binding to acetylcholinesterase (AChE) using positron emission tomography (PET). Donepezil is an AChE inhibitor that is widely prescribed to ameliorate the cognitive impairment of patients with dementia. Six healthy subjects took part in a dynamic study involving a 60-min PET scan after intravenous injection of [(11)C]donepezil. The total distribution volume (tDV) of [(11)C]donepezil was quantified by compartmental kinetic analysis and Logan graphical analysis. A one-tissue compartment model (1TCM) and a two-tissue compartment model (2TCM) were applied in the kinetic analysis. Goodness of fit was assessed with chi(2) criterion and Akaike&apos;s Information Criterion (AIC). Compared with a 1TCM, goodness of fit was significantly improved by a 2TCM. The tDVs provided by Logan graphical analysis were slightly lower than those provided by a 2TCM. The rank order of the mean tDVs in 10 regions was in line with the AChE activity reported in a previous post-mortem study. Logan graphical analysis generated voxel-wise images of tDV, revealing the overall distribution pattern of AChE in individual brains. Significant correlation was observed between tDVs calculated with and without metabolite correction for plasma time-activity curves, indicating that metabolite correction could be omitted. In conclusion, this method enables quantitative analysis of AChE and direct investigation of the pharmacokinetics of donepezil in the human brain. (C) 2009 Elsevier Inc. All rights reserved.

  60. 124Iを使用したNIS遺伝子発現イメージング法の開発 超音波とナノバブルを利用した遺伝子デリバリー

    渡邊 夕紀子, 堀江 佐知子, 船木 善仁, 菊池 洋平, 山崎 浩道, 石井 慶造, 森 士朗, 小玉 哲也

    Drug Delivery System 24 (3) 364-364 2009年6月

    出版者・発行元:日本DDS学会

    ISSN:0913-5006

    eISSN:1881-2732

  61. Evaluation of Drug Half-life in the Brain after Oral Administration of Antihistamines using PET and [11C]Doxepin.

    Zhang D, Tashiro M, Shibuya K, Funaki Y, Okamura N, Kato M, Yanai K

    Proceedings of 3rd Student Workshop of Tohoku University Global COE Program Nano-Biomedical Engineering Education and Research Network Centre. 2009年

  62. Quantification of Amyloid β Deposition in Alzheimer's Disease Patients Using PET and [11C]BF-227.

    Tashiro M, Okamura N, Watanuki S, Furumoto S, Furukawa K, Funaki Y, Iwata R, Kudo Y, Arai H, Watabe H, Yanai K

    CYRIC Annual Report 2009 164-170 2009年

    出版者・発行元:Cyclotron and Radioisotope Center, Tohoku University

    詳細を見る 詳細を閉じる

    CYRIC Annual Report 2009

  63. Quantitative Analysis of Donepezil Binding to Acetylcholinesterase Using PET and [5-11C-methoxy]Donepezil.

    Hiraoka K, Okamura N, Funaki Y, Watanuki S, Tashiro M, Kato M, Hayashi A, Hosokai Y, Yamasaki H, Fujii T, Mori E, Yanai K, Watabe H

    CYRIC Annual Report 2009 171-173 2009年

    出版者・発行元:Cyclotron and Radioisotope Center, Tohoku University

    詳細を見る 詳細を閉じる

    CYRIC Annual Report 2009

  64. Hangover Effect of Orally Administered Antihistamines Measured by Brain Histamine H1 Receptor Occupancy Using PET and 11C-doxepin: A Comparison between Diphenhydramine and Bepotastine in Healthy Subjects.

    Zhang D, Tashiro M, Okamura N, Shibuya K, Funaki Y, Watanuki S, Yanai K

    CYRIC Annual Report 2009 174-178 2009年

    出版者・発行元:Cyclotron and Radioisotope Center, Tohoku University

    詳細を見る 詳細を閉じる

    CYRIC Annual Report 2009

  65. Production of "no carrier added” iodine-124 from a reusable enriched tellurium-124 dioxide target and its application to an ultra-high resolution animal PET study 査読有り

    Yamazaki H, Ishii K, Funaki Y, Kanai Y, Y, Kikuchi Y, Watanabe Y, Kodama T, Hatazawa J, Matsuyama S, Sabet H, Terakawa A

    The 16th Pacific Basin Nuclear Conference P16P1299 2008年10月13日

  66. 各種疾患マウス前脛骨筋でのPETによるNIS遺伝子発現の確認

    渡邊 夕紀子, 堀江 佐知子, 冨田 典子, 大澤 ふき, 船木 善仁, 菊池 洋平, 中村 賢治, 中沢 浩一, 山崎 浩道, 石井 慶造, 福本 学, 森 士朗, 小玉 哲也

    核医学 45 (3) S204-S204 2008年9月

    出版者・発行元:(一社)日本核医学会

    ISSN:0022-7854

    eISSN:2189-9932

  67. 癌性疼痛緩和およびPETによるイメージング(Cancer pain control and PET imaging)

    渡邊 夕紀子, 堀江 佐知子, 冨田 典子, 陳 鋭, 大澤 ふき, 船木 善仁, 菊池 洋平, 山崎 浩道, 石井 慶造, 小野 栄夫, 福本 学, 森 士朗, 小玉 哲也

    日本癌学会総会記事 67回 388-388 2008年9月

    出版者・発行元:日本癌学会

    ISSN:0546-0476

  68. 軽度認知障害におけるBF227-PET画像所見

    岡村信行, 古本祥三, 田代学, 古川勝敏, 船木善仁, 岩田錬, 荒井啓行, 工藤幸司, 谷内一彦

    核医学 45 (3) S182-S182 2008年9月

    出版者・発行元:(一社)日本核医学会

    ISSN:0022-7854

    eISSN:2189-9932

  69. アルツハイマー病患者のドネペジルPET所見とドネペジル投与の臨床的効果

    糟谷昌志, 石川博康, 岡村信行, 加藤元久, 佐々木由美, 中田江梨子, 石川洋一, 船木善仁, 田中尚文, 岩田錬, 谷内一彦, 目黒謙一

    Dementia Japan 22 (2) 185-185 2008年8月

    出版者・発行元:(一社)日本認知症学会

    ISSN:1342-646X

  70. ナノバブルと超音波を利用した炎症疾患モデルマウスでのNa/I sympoter(NIS)遺伝子発現の可視化

    渡邊 夕紀子, 堀江 佐知子, 冨田 典子, 大澤 ふき, 船木 善仁, 菊池 洋平, 山崎 浩道, 石井 慶造, 森 士朗, 小玉 哲也

    超音波医学 35 (4) 469-469 2008年7月

    出版者・発行元:(公社)日本超音波医学会

    ISSN:1346-1176

    eISSN:1881-9311

  71. Brain histamine H(1) receptor occupancy of orally administered antihistamines, bepotastine and diphenhydramine, measured by PET with (11)C-doxepin 査読有り

    Manabu Tashiro, Xudong Duan, Motohisa Kato, Masayasu Miyake, Shoichi Watanuki, Yoichi Ishikawa, Yoshihito Funaki, Ren Iwata, Masatoshi Itoh, Kazuhiko Yanai

    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY 65 (6) 811-821 2008年6月

    出版者・発行元:WILEY-BLACKWELL

    DOI: 10.1111/j.1365-2125.2008.03143.x  

    ISSN:0306-5251

    eISSN:1365-2125

    詳細を見る 詳細を閉じる

    AIMS Antihistamines are frequently used for treating various allergic diseases, but often induce sedation. The degree of sedation can be evaluated by measuring histamine H(1) receptor occupancy (H(1)RO) in the brain using positron emission tomography (PET). The aim was to measure H(1)RO of bepotastine, a new second-generation antihistamine, and to compare it with that of diphenhydramine. METHODS Eight healthy male volunteers (mean age +/- SD 24.4 +/- 3.3 years) were studied after single oral administration of bepotastine (10 mg), diphenhydramine (30 mg) or placebo, by PET imaging with (11)C-doxepin in a crossover study design. Binding potential ratio and H(1)ROs were calculated using placebo data and were compared between bepotastine and diphenhydramine in the anterior and posterior cingulate gyri (ACG and PCG, respectively), superior and inferior frontal cortices (SFC and IFC, respectively), orbitofrontal cortex (OFC), insular cortex (IC), lateral and medial temporal cortices (LTC and MTC, respectively), parietal cortex (PC), occipital cortex (OC) and sensorimotor cortex (SMC). Plasma concentration of each antihistamine was measured, and its correlation to H(1)RO was examined. RESULTS H(1)RO after bepotastine treatment was significantly lower than that after diphenhydramine treatment in all cortical regions (P &lt; 0.001). Mean H(1)ROs of bepotastine and diphenhydramine were 14.7% and 56.4%, respectively. H(1)ROs of both bepotastine and diphenhydramine correlated to their respective drug plasma concentration (P &lt; 0.001). CONCLUSION Oral bepotastine (10 mg), with its relatively low H(1)RO and thus minimal sedation, has the potential for use as a mildly or slightly sedative antihistamine in the treatment of various allergic disorders.

  72. In vivo visualization of donepezil binding in the brain of patients with Alzheimer’s disease 査読有り

    Nobuyuki Okamura, Yoshihito Funaki, Manabu Tashiro, Motohisa Kato, Yoichi Ishikawa, Masahiro Maruyama, Hiroyasu Ishikawa, Kenichi Meguro, Ren Iwata, Kazuhiko Yanai

    British Journal of Clinical Pharmacology 65 (4) 472-479 2008年4月

    出版者・発行元:None

    DOI: 10.1111/j.1365-2125.2007.03063.x  

    ISSN:0306-5251

  73. In vivo visualization of donepezil binding in the brain of patients with Alzheimer&apos;s disease 査読有り

    Nobuyuki Okamura, Yoshihito Funaki, Manabu Tashiro, Motohisa Kato, Yoichi Ishikawa, Masahiro Maruyama, Hiroyasu Ishikawa, Kenichi Meguro, Ren Iwata, Kazuhiko Yanai

    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY 65 (4) 472-479 2008年4月

    出版者・発行元:WILEY-BLACKWELL

    DOI: 10.1111/j.1365-2125.2007.03063.x  

    ISSN:0306-5251

    詳細を見る 詳細を閉じる

    AIMS The aims of this study were to visualize in vivo binding of donepezil to acetylcholinesterase (AChE) in the brain and to establish a method for measuring the amount of binding of orally administered donepezil. METHODS [5-(11)C-methoxy]-donepezil ([(11)C]-donepezil) was radiolabelled as a positron emission tomography (PET) tracer. The biodistribution of [(11)C]-donepezil was measured by PET in 10 AD patients and six elderly normal subjects. Two AD patients underwent additional PET measurements after oral administration of donepezil for 6 months. RESULTS [(11)C]-donepezil-PET images demonstrated high densities of tracer distribution in AChE-rich brain regions such as the striatum, thalamus, and cerebellum. Compared with elderly normal subjects, patients with mild AD exhibited about 18-20% reduction of donepezil binding in the neocortex and hippocampus, while patients with moderate AD exhibited about 24-30% reduction of donepezil binding throughout the brain. Orally administered donepezil (5 mg day(-1)) induced 61.6-63.3% reduction of donepezil binding in AD brains. The distribution volume of [(11)C]-donepezil in the hippocampus was significantly correlated with MMSE scores in AD patients. CONCLUSIONS [(11)C]-donepezil-PET enables quantitative measurement of donepezil binding in the brain. AD patients exhibited reduction of donepezil binding in the brain, even in the early stage of disease. Longitudinal evaluation by this technique enables determination of AChE binding occupancy of orally administered donepezil.

  74. High resolution semiconductor animal PET 査読有り

    Keizo Ishii, Youhei Kikuchi, Shigeo Matsuyama, Yasukazu Kanai, Koji Kotani, Takashi Itoh, Hiromichi Yamazaki, Yoshihito Funaki, Ren Iwata, Masatoshi Itoh, Kazuhiko Yanai, Jun Hatazawa, Nobuhiko Itoh, Naoaki Tanizaki, Daizo Amano, Manabu Yamada, Takashi Yamaguchi

    CURRENT MEDICAL IMAGING REVIEWS 4 (1) 51-55 2008年2月

    出版者・発行元:BENTHAM SCIENCE PUBL LTD

    DOI: 10.2174/157340508783502831  

    ISSN:1573-4056

    詳細を見る 詳細を閉じる

    A positron emission tomography ( PET) for animals using cadmium telluride (CdTe) detectors was developed for the purpose of biomedical study using rats and mice. The spatial resolution of 0.8mm FWHM within the central 20 mm-diameter of field of view (FOV) was obtained by the use of small CdTe elements of 1.1 mm x 1.0 mm x 5 mm. The FOV is 64 mm in diameter and 26 mm in axis. Fine images were successively obtained following [F-18] fluorodeoxyglucose ([F-18]FDG) injection to a rat and a mouse. In the fine [F-18]FDG images, the cerebral cortex, the gray matter and the corpus striatum was able to be respectively distinguished.

  75. 1613 マウス骨格筋でのNa/I symporter(NIS)遺伝子発現の可視化(S22 ドラッグデリバリーシステムと流体力学,21世紀地球環境革命の機械工学:人・マイクロナノ・エネルギー・環境)

    渡邊 夕紀子, 堀江 佐知子, 冨田 典子, 大澤 ふき, 陳 鋭, 船木 善仁, 菊池 洋平, 山崎 浩道, 石井 慶造, 森 士朗, 小玉 哲也

    年次大会講演論文集 2008 23-24 2008年

    出版者・発行元:一般社団法人日本機械学会

    DOI: 10.1299/jsmemecjo.2008.2.0_23  

    詳細を見る 詳細を閉じる

    A non-invasive molecular delivery method using nano/microbubbles (NB) and ultrasound (US) is an attractive technique for gene therapy. This method is able to deliver macromolecules such as plasmid DNA to a tissue specific site non-invasively. In addition, a non-invasive quantification method of gene expression has been studied by monitoring ^<124> accumulation caused by the of Na/I symporter (NIS) gene expression with positron emission tomography (PET). In the present study, we delivered NIS gene into the skeletal muscle of vasculitis and muscular dystrophy mice by using the US/NB method, and succeed in visualizing the ^<124>I accumulation caused by NIS gene expression in the muscle with PET. The combination of the US/NB delivery with NIS/PET visualization will be a valuable methodology in gene therapy.

  76. FDG Imaging of 1mm Tumor with an Ultra High Resolution Animal PET 査読有り

    Keizo Ishii, Yoshihito Funaki, Youhei Kikuch, Hiromichi Yamazaki, Shigeo Matsuyama, Atsuki Terakawa, Mitsuhiro Fujiwara, Ren Iwata, Tetsuya Kodama, Yukiko Watanabe, Naoto Tanizaki, Daizo Amano, Takashi Yamaguchi

    Proceeding of International Symposium on Biomedical Imaging 2008 1589-1592 2008年

    DOI: 10.1109/ISBI.2008.4541315  

  77. アルツハイマー病患者脳内におけるドネペジル結合量の定量化

    岡村信行, 加藤元久, 船木善仁, 田代学, 目黒謙一, 谷内一彦

    日本薬理学雑誌 131 (1) 3P-3P 2008年1月

    出版者・発行元:(公社)日本薬理学会

    ISSN:0015-5691

    eISSN:1347-8397

  78. In Vivo Measurement of Cholinesterase Density in the Brain using [11C]donepezil.

    Okamura N, Kato M, Funaki Y, Tashiro M, Yanai K

    Proceedings of 5th International Symposium of Tohoku University Global COE Program Nano-Biomedical Engineering Education and Research Network Centre. 67-70 2008年

  79. Tumor Growth Delay Caused by Proton Therapy in Combination with the Vascular Disrupting Agent AVE8062.

    Terakawa A, Ishii K, Matsuyama S, Kikuchi Y, Akiyama H, Koyata K, Ito Y, Tagawa A, Yasunaga S, Yamazaki H, Tashiro M, Funaki Y, Furumoto S, Itoh N, Wada S, Orihara H

    CYRIC Annual Report 2008 65-68 2008年

    出版者・発行元:Cyclotron and Radioisotope Center, Tohoku University

    詳細を見る 詳細を閉じる

    CYRIC Annual Report 2008

  80. Increased Histamine H1 Receptor Ooccupancy Following Treatment with an Exceeded Dose of Cetirizine Hydrochloride, a Mildly-sedative Antihistamine.

    Tashiro M, Kato M, Miyake M, Watanuki S, Funaki Y, Ishikawa Y, Iwata R, Yanai K

    CYRIC Annual Report 2008 149-153 2008年

    出版者・発行元:Cyclotron and Radioisotope Center, Tohoku University

    詳細を見る 詳細を閉じる

    CYRIC Annual Report 2008

  81. Amyloid PET and Voxel-based Morphometry Analysis Using MRI in Mild Cognitive Impairment and Alzheimer's Disease.

    Waragai M, Okamura N, Furukawa K, Tashiro M, Watanuki S, Furumoto S, Funaki Y, Kato M, Iwata R, Yanai K, Kudo Y, Arai H

    CYRIC Annual Report 2008 154-159 2008年

    出版者・発行元:Cyclotron and Radioisotope Center, Tohoku University

    詳細を見る 詳細を閉じる

    CYRIC Annual Report 2008

  82. Quantitative Analysis of Donepezil Binding to Acetylcholinesterase Using Positron Emission Tomography and [5-11C-methoxy]Donepezil.

    Hiraoka K, Okamura N, Funaki Y, Watanuki S, Tashiro M, Kato M, Hayashi A, Hosokai Y, Yamasaki H, Fujii T, Mori E, Yanai K, Watabe H

    CYRIC Annual Report 2008 168-171 2008年

    出版者・発行元:Cyclotron and Radioisotope Center, Tohoku University

    詳細を見る 詳細を閉じる

    CYRIC Annual Report 2008

  83. PET measurement of amyloid deposition in the brain of neurodegenerative disease using BF-227 査読有り

    Nobuyuki Kamura, Yukitsuka Kudo, Shozo Furumoto, Manabu Tashiro, Motohisa Kato, Yoshihito Funaki, Masanori Mori, Katsumi Doh-ura, Hiroyuki Arai, Kazuhiko Yanai

    JOURNAL OF PHARMACOLOGICAL SCIENCES 106 (1) 115P-115P 2008年

    出版者・発行元:JAPANESE PHARMACOLOGICAL SOC

    ISSN:1347-8613

  84. In vivo visualization of [C-11]donepezil binding in the brain of patients with Alzheimer's disease 査読有り

    Motohisa Kato, Nobuyuki Okamura, Yoshihito Funaki, Manabu Tashiro, Yoichi Ishikawa, Masahiro Maruyama, Hiroyasu Ishikawa, Kenichi Meguro, Ren Iwata, Kazuhiko Yanai

    JOURNAL OF PHARMACOLOGICAL SCIENCES 106 (1) 182P-182P 2008年

    出版者・発行元:JAPANESE PHARMACOLOGICAL SOC

    ISSN:1347-8613

  85. Binding and safety profile of novel benzoxazole derivative for in vivo imaging of amyloid deposits in Alzheimer's disease 査読有り

    Nobuyuki Okamura, Shozo Furumoto, Yoshihito Funaki, Takahiro Suemoto, Motohisa Kato, Yoichi Ishikawa, Satoshi Ito, Hiroyasu Akatsu, Takayuki Yamamoto, Tohru Sawada, Hiroyuki Arai, Yukitsuka Kudo, Kazuhiko Yanai

    GERIATRICS & GERONTOLOGY INTERNATIONAL 7 (4) 393-400 2007年12月

    出版者・発行元:BLACKWELL PUBLISHING

    DOI: 10.1111/j.1447-0594.2007.00430.x  

    ISSN:1444-1586

    詳細を見る 詳細を閉じる

    Background: In vivo detection of amyloid deposits in the brain is potentially useful for early diagnosis of Alzheimer's disease (AD) and tracking the efficacy of anti-amyloid therapy. Methods: To develop an amyloid-binding agent for positron emission tomography, we screened over 2600 compounds. Results: We found benzoxazole derivatives as candidate compounds for in vivo amyloid imaging probes. One of these agents, 2-(2-[2-dimethylaminothiazol-5-yl]ethenyl)-6-(2[fluoro]ethoxy)benzoxazole (BF-227), displays high binding affinity to A beta fibrils. BF-227 binding increased linearly with increasing A beta fibril formation. In temporal and hippocampal AD brain sections, BF-227 selectively bound to amyloid plaques. In contrast, no staining was evident in the cerebellum. Compared with the previously reported compound BF-168, F-18-labeled BF-227 displayed selective in vivo labeling of amyloid fibrils and rapid washout from white matter areas in an A beta-injected rat model. An acute and subacute toxicity study of BF-227 indicated sufficient safety for clinical use as a positron emission tomography probe. Conclusions: These findings suggest that BF-227 is feasible as an in vivo imaging probe of amyloid deposits in AD patients.

  86. Brain histamine H1 receptor occupancy of a new antihistamine, bepotastine, measured by PET and [11C]doxepin

    Manabu Tashiro, Duan Xudong, Motohisa Kato, Masayasu Miyake, Shouichi Watanuki, Youichi Ishikawa, Yoshihito Funaki, Ren Iwata, Masatoshi Itoh, Kazuhiko Yanai

    Journal of Cerebral Blood Flow and Metabolism 27 (SUPPL. 1) 2007年11月13日

    ISSN:0271-678X

    詳細を見る 詳細を閉じる

    Background and aims: Histamine H1 receptor (H1R) antagonists, or antihistamines, are often used for treatment of allergic disorders such as seasonal rhinitis. Antihistamines mainly act on the peripheral tissues but can induce sedation. This undesirable central side effect is caused by blockade of nerve transmission in the histaminergic neuron system. First-generation antihistamines such as diphenhydramine can easily penetrate blood-brain barrier (BBB) and tend to occupy a large proportion of post-synaptic H1Rs. Second-generation antihistamines such as fexofenadine and olopatadine can slightly penetrate BBB and H1Rs are slightly occupied. Thus, variation in cerebral H1R occupancy (H1RO) of antihistamines results mainly from their different BBB permeability. The aim of the present study was to compare the sedative property of a new antihistamine, bepotastine, in terms of H1RO using PET and [11C]doxepin. Methods: Eight healthy male volunteers (mean age +/- s.d.: 24.4 +/- 3.3 years old) were studied after single oral administration of bepotastine 10 mg, diphenhydramine 30 mg (a typical sedative antihistamine), or placebo, using PET and [11C]doxepin in a crossover study-design. Binding potential ratio and H1R occupancy values were calculated using placebo data, and were compared between bepotastine and diphenhydramine. PET brain images were reconstructed with a filtered back projection algorithm. The brain images were then normalized by plasma radioactivity at 10 min post-injection to yield static distribution volume (DV) images. H1RO of bepotastine was compared to that of diphenhydramine. The present study was approved by the Committee on Clinical Investigation at Tohoku University Graduate School of Medicine, Japan. All experiments were performed at the Cyclotron and Radioisotope Centre, Tohoku University. Results: Brain images following administration of bepotastine demonstrated slightly lower binding potential in comparison to those following placebo, and images following diphenhydramine administration demonstrated significantly lower binding potential in comparison to both placebo and bepotastine. Overall cortical mean H1RO of bepotastine and diphenhydramine were 15% and 57%, respectively. H1R occupancy of both bepotastine and diphenhydramine correlated well with their respective drug plasma concentration (p< 0.001). Conclusions: In the present study, H1ROs following oral administration of bepotastine 10 mg or diphenhydramine 30 mg were calculated as 14.8% and 56.8%, respectively. In our previous studies, our previous PET studies demonstrated that first-generation antihistamines occupied more than 50% of available H1Rs. The result of bepotastine (15%) is in accordance with the categorization of bepotastine as a second-generation antihistamine. Previous studies have demonstrated H1ROs of other second-generation antihistamines such as terfenadine 60 mg (12-17%), fexofenadine 120 mg (1%) and ebastine 10 mg (10%). As a whole, second-generation antihistamines seem to occupy around 0 to 20% of brain H1Rs. In conclusion, PET and [11C]doxepin is useful for evaluating sedative side effects of various psychoactive drugs with antihistamine effects. Collection of more H1RO data is encouraged for establishment of a reliable international database for evaluation of the sedative profile of psychoactive drugs.

  87. Evaluation of the binding characteristics of [F-18]fluoroproxyfan in the rat brain for in vivo visualization of histamine H-3 receptor 査読有り

    Yoshihito Funaki, Kimihiko Sato, Motohisa Kato, Yolchi Ishikawa, Ren Iwata, Kazuhiko Yanai

    NUCLEAR MEDICINE AND BIOLOGY 34 (8) 981-987 2007年11月

    出版者・発行元:ELSEVIER SCIENCE INC

    DOI: 10.1016/j.nucmedbio.2007.07.012  

    ISSN:0969-8051

    詳細を見る 詳細を閉じる

    Histamine H-3 receptors play an important role in biological functions. The aim of this research was to examine whether histamine H3 receptors can be visualized in vivo and in vitro with [F-18]3-(1H-imidazol-4-yl)propyI 4-fluorobenzyl ether (fluoroproxyfan). [F-18] Fluoroproxyfan was synthesized with high specific activity using [18F]benzyl bromide. The binding of [18F]fluoroproxyfan to rat brain homogenates was higher in the striatum and thalamus and was lowest in the cerebellum. The in vitro autoradiographic study successfully demonstrated the specific binding of [F-18]fluoroproxyfan to the H3 receptor in the rat brain. In accordance with the in vitro bindings, the in vivo distribution of [18F]fluoroproxyfan was heterogeneous in the rat brain. In the blocking experiments, the heterogeneous distribution disappeared in the presence of large amounts of fluoroproxyfan. These data suggest that [18F]fluoroproxyfan can be potentially useful to image histamine H3 receptor noninvasively in the human brain by positron emission tomography. (c) 2007 Elsevier Inc. All rights reserved.

  88. [11C]donepezil-PETを用いたドネペジル投与後の脳内分布の画像化

    加藤元久, 岡村信行, 船木善仁, 田代学, 谷内一彦

    核医学 44 (3) 323-323 2007年10月

    出版者・発行元:(一社)日本核医学会

    ISSN:0022-7854

    eISSN:2189-9932

  89. 弱鎮静性抗ヒスタミン薬内服後の脳内ヒスタミン受容体占拠率に関する用量依存性の検討

    田代学, 加藤元久, 船木善仁, 石川洋一, 四月朔日聖一, 岩田錬, 伊藤正敏, 谷内一彦

    核医学 44 (3) 313-313 2007年10月

  90. [11C]BF-227を用いた脳内アミロイド蓄積に関する定量的検討

    田代学, 岡村信行, 熊谷和明, 古本祥三, 船木善仁, 木村雄一, 石渡喜一, 岩田錬, 工藤幸司, 荒井啓行, 谷内一彦

    核医学 44 (3) 301-301 2007年10月

    出版者・発行元:(一社)日本核医学会

    ISSN:0022-7854

    eISSN:2189-9932

  91. First achievement of less than 1 mm FWHM resolution in practical semiconductor animal PET scanner 査読有り

    K. Ishii, Y. Kikuchi, S. Matsuyama, Y. Kanai, K. Kotani, T. Ito, H. Yamazaki, Y. Funaki, R. Iwata, M. Itoh, K. Yanai, J. Hatazawa, N. Itoh, N. Tanizaki, D. Amano, M. Yamada, T. Yamaguchi

    NUCLEAR INSTRUMENTS & METHODS IN PHYSICS RESEARCH SECTION A-ACCELERATORS SPECTROMETERS DETECTORS AND ASSOCIATED EQUIPMENT 576 (2-3) 435-440 2007年6月

    出版者・発行元:ELSEVIER SCIENCE BV

    DOI: 10.1016/j.nima.2007.03.018  

    ISSN:0168-9002

    詳細を見る 詳細を閉じる

    An animal PET scanner using CdTe detectors was developed for the purpose of biomedical study using mice and rats. A spatial resolution of 0.8 mm FWHM within the central 20 mm-diameter of the field of view (FOV) was obtained by small CdTe elements of 1.1 mm x 5.0 mm x 1.0 mm. This spatial resolution is the first achievement of a practical semiconductor animal PET scanner. The determination of the depth of the 7 interaction in the detector was carried out by the use of two detector layers. The FOV is 64 mm in diameter and 26 mm in axis. Fine [F-18]FDG images of the heads of a mouse and a rat, where the cerebral cortex, the gray matter and the corpus striatum could be respectively distinguished, were successfully obtained. This work inspires the dawn of the high resolution semiconductor PET scanner age as the next generation. (C) 2007 Elsevier B.V. All rights reserved.

  92. Evaluation of the regional distribution of acetylcholinesterase in the living human brain using [11C]donepezil and PET 査読有り

    Yoshihito Funaki, Nobuyuki Okamura, Motohisa Kato, Manabu Tashiro, Youichi Ishikawa, Ren Iwata, Kazuhiko Yanai

    Journal of Nuclear Medicine 2007年6月

  93. Initial evaluation of dynamic human imaging using F-18-FRP170 as a new PET tracer for imaging hypoxia 査読有り

    Tomohiro Kaneta, Yoshihiro Takai, Ren Iwata, Takashi Hakamatsuka, Hiroyasu Yasuda, Katsutoshi Nakayama, Yoichi Ishikawa, Shoichi Watanuki, Shozo Furumoto, Yoshihito Funaki, Eiko Nakata, Keiichi Jingu, Michihiko Tsujitani, Masatoshi Ito, Hiroshi Fukuda, Shoki Takahashi, Shogo Yamada

    ANNALS OF NUCLEAR MEDICINE 21 (2) 101-107 2007年2月

    出版者・発行元:JAPANESE SOCIETY NUCLEAR MEDICINE

    DOI: 10.1007/BF03033987  

    ISSN:0914-7187

    詳細を見る 詳細を閉じる

    F-18-FRP170, 1-(2-fluoro-1-[hydroxymethyl]ethoxy)methyl-2-nitroimidazole, is a new hypoxia imaging agent for positron emission tomography. This compound was synthesized by F-18-labeling of RP170, which was developed as a new hydrophilic 2-nitroimidazole analog. In the present study, we analyzed dynamic whole-body imaging in healthy volunteers and dynamic tumor imaging in three patients with lung cancer. Methods: Four healthy male volunteers and three lung cancer patients were enrolled in this study. Volunteers underwent dynamic whole-body scans just after injection of F-18-FRP170 for about 90 min, while the lung cancer patients underwent dynamic tumor imaging for about 60 or 120 min. Data are expressed as standardized uptake values (SU-V). Regions of interest were placed over images of each organ or tumor to generate time-SUV curves. Results: The series of dynamic whole-body scans showed rapid elimination of F-18-FRP170 from the kidneys following elimination from the liver. Very low physiological uptake was observed above the diaphragm. F-18-FRP170 uptake in the lung cancer lesion could be visualized clearly from early after injection. The changes of tumor SUV, tumor/blood ratio, or tumor/muscle ratio about 30 min after injection or later were small. Conclusions: Dynamic imaging using F-18-FRP170 demonstrated rapid elimination from the kidney, suggesting the high hydrophilicity of this imaging agent. The background activity above the diaphragm was very low, and patients with lung cancer showed clear tumor uptake of F-18-FRP170 early after injection.

  94. Relationship between Brain Histamine H1 Receptor Occupancy, Subjective Sleepiness and Plasma Drug Concentration Following Oral Administration of Antihistamines Bepotastine and Diphenhydramine.

    Tashiro M, Duan X, Kato M, Miyake M, Watanuki S, Ishikawa Y, Funaki Y, Iwata R, Itoh M, Yanai K

    CYRIC Annual Report 2007 81-85 2007年

    出版者・発行元:Cyclotron and Radioisotope Center, Tohoku University

    詳細を見る 詳細を閉じる

    CYRIC Annual Report 2007

  95. 新規アミロイドイメージング剤[11C]BF227の臨床評価

    古本祥三, 岡村信行, 田代学, 船木善仁, 石川洋一, 古川勝敏, 伊藤正敏, 岩田錬, 谷内一彦, 荒井啓行, 工藤幸司

    核医学 43 (3) 235-235 2006年10月

    出版者・発行元:(一社)日本核医学会

    ISSN:0022-7854

    eISSN:2189-9932

  96. がんの機能イメージング 新低酸素細胞イメージング剤[18F]FRP-170の開発と臨床応用

    高井 良尋, 金田 朋洋, 袴塚 崇, 仲田 栄子, 岩田 錬, 船木 善仁, 石川 洋一, 辻谷 典彦

    日本放射線影響学会大会講演要旨集 49回 62-62 2006年9月

    出版者・発行元:(一社)日本放射線影響学会

    ISSN:1347-8680

  97. ヒスタミンH3受容体の可視化を目的とした新規ポジトロン放出薬剤の開発

    船木善仁

    INNERVISION 21 (7) 22 2006年7月

  98. 老人斑画像化プローブ[11C]BF227の合成と評価

    古本祥三, 岡村信行, 石川洋一, 船木善仁, 加藤元久, 田代学, 澤田徹, 伊藤正敏, 谷内一彦, 岩田錬, 荒井啓行, 工藤幸司

    日本薬学会年会要旨集 126年会 (2) 68-68 2006年3月

    出版者・発行元:(公社)日本薬学会

    ISSN:0918-9823

  99. In Vivo Imaging of Donepezil Binding in the Brain Using [11C]Donepezil-PET.

    Okamura N, Funaki Y, Tashiro M, Kato M, Ishikawa Y, Ishikawa H, Meguro K, Iwata R, Itoh M, Yanai K

    CYRIC Annual Report 2006 105-108 2006年

    出版者・発行元:Cyclotron and Radioisotope Center, Tohoku University

    詳細を見る 詳細を閉じる

    CYRIC Annual Report 2006

  100. 期待されるFDG以外の腫瘍PETイメージング製剤 新低酸素細胞イメージング剤[18F]FRP-170の開発と臨床応用

    高井 良尋, 金田 朋洋, 袴塚 崇, 岩田 錬, 船木 善仁, 古本 祥三, 仲田 栄子, 工藤 幸司, 山田 章吾

    核医学 42 (3) 260-260 2005年9月

    出版者・発行元:(一社)日本核医学会

    ISSN:0022-7854

    eISSN:2189-9932

  101. PETを用いた健常者およびアルツハイマー患者における[11C]donepezilの分布評価

    船木善仁, 岡村信行, 加藤元久, 田代学, 石川洋一, 岩田錬, 谷内一彦

    日本薬学会年会要旨集 125年会 (2) 80-80 2005年3月

    出版者・発行元:(公社)日本薬学会

    ISSN:0918-9823

  102. Evaluation of the regional distribution of acetylcholinesterase in the living brain using [11C]donepezil and PET 査読有り

    Y. Funaki, N. Okamura, M. Kato, M. Tashiro, Y. Ishikawa, R. Iwata, K. yanai

    The 7th internationl meetings of AD/PD 29 2005年3月

  103. Brain histamine H1 receptor occupancy of antihistamines, bepotastine and diphenhydramine, measured by [11C]doxepin PET.

    Duan X, Tashiro M, Kato M, Miyake M, Watanuki S, Ishikawa S, Funaki Y, Iwata R, Itoh M, Yanai K

    CYRIC Annual Report 2005 120-123 2005年

    出版者・発行元:Cyclotron and Radioisotope Center, Tohoku University

    詳細を見る 詳細を閉じる

    CYRIC Annual Report 2005

  104. Benzoxazole誘導体のアミロイドイメージング用プローブとしての有用性の検討

    岡村信行, 加藤元久, 谷内一彦, 古本祥三, 工藤幸司, 船木善仁, 岩田錬, 島津浩, 澤田徹, 赤津裕康, 山本孝之

    核医学 41 (3) 380-380 2004年9月

    出版者・発行元:(一社)日本核医学会

    ISSN:0022-7854

    eISSN:2189-9932

  105. アセチルコリンエステラーゼ阻害剤TAK-147の18F-標識化と脳における可視化剤としての検討

    加藤元久, 船木善仁, 岩田錬, 石川洋一, 谷内一彦

    核医学 41 (3) 379-380 2004年9月

  106. PETを用いた健常者における[11C]donepezilの分布評価

    船木善仁, 岡村信行, 加藤元久, 田代学, 石川洋一, 岩田錬, 谷内一彦

    核医学 41 (3) 311-311 2004年9月

    出版者・発行元:(一社)日本核医学会

    ISSN:0022-7854

    eISSN:2189-9932

  107. Decreased histamine H-1 receptor binding in the brain of depressed patients 査読有り

    M Kano, S Fukudo, A Tashiro, A Utsumi, D Tamura, M Itoh, R Iwata, M Tashiro, H Mochizuki, Y Funaki, M Kato, M Hongo, K Yanai

    EUROPEAN JOURNAL OF NEUROSCIENCE 20 (3) 803-810 2004年8月

    出版者・発行元:BLACKWELL PUBLISHING LTD

    DOI: 10.1111/j.1460-9568.2004.03540.x  

    ISSN:0953-816X

    詳細を見る 詳細を閉じる

    The central histaminergic neuron system modulates the wakefulness, sleep-awake cycle, appetite control, learning and memory, and emotion. Previous studies have reported changes in neuronal histamine release and its metabolism under stress conditions in the mammalian brain. In this study, we examined, using positron emission tomography (PET) and [C-11]-doxepin, whether the histaminergic neuron system is involved in human depression. Cerebral histamine H1 receptor (H1R) binding was measured in 10 patients with major depression and in 10 normal age-matched subjects using PET and [C-11]-doxepin. Data were calculated by a graphical analysis on voxel-by-voxel and ROI (region of interests) basis. Binding potential (BP) values for [C-11]-doxepin binding in the frontal and prefrontal cortices, and cingulate gyrus were significantly lower in the depressed patients than those in the normal control subjects. There was no area of the brain where [C-11]-doxepin binding was significantly higher in the depressed patients than in the controls. ROI-based analysis also revealed that BP values for [C-11]-doxepin binding in the frontal cortex and cingulate gyrus decreased in proportion to self-rating depressive scales scores. The results of this study demonstrate that depressed patients have decreased brain H1R binding and that this decrease correlates with the severity of depression symptoms. It is therefore suggested that the histaminergic neuron system plays an important role in the pathophysiology of depression and that its modulation may prove to be useful in the treatment of depression.

  108. Central effects of fexofenadine and cetirizine: Measurement of psychomotor performance, subjective sleepiness, and brain histamine H-1-receptor occupancy using C-11-doxepin positron emission tomography 査読有り

    M Tashiro, Y Sakurada, K Iwabuchi, H Mochizuki, M Kato, M Aoki, Y Funaki, M Itoh, R Iwata, DF Wong, K Yanai

    JOURNAL OF CLINICAL PHARMACOLOGY 44 (8) 890-900 2004年8月

    出版者・発行元:SAGE PUBLICATIONS INC

    DOI: 10.1177/0091270004267590  

    ISSN:0091-2700

    詳細を見る 詳細を閉じる

    Histamine H1-receptor (H1R) antagonists, or antihistamines, often induce sedative side effects when used for the treatment of allergic disorders. This study compared the sedative profiles of the second-generation antihistamines, fexofenadine and cetirizine, using 3 different criteria: subjective sleepiness evaluated by the Stanford Sleepiness Scale, objective psychomotor tests (simple and choice reaction time tests and visual discrimination tests at 4 different exposure durations), and measurement of histamine H1-receptor occupancy (H1RO) in the brain. Subjective sleepiness and psychomotor performance were measured in 20 healthy Japanese volunteers at baseline and 90 min after administration of fexofenadine 120 mg or cetirizine 20 mg in a double-blind, placebo-con trolled crossover study. Hydroxyzine 30 mg was included as a positive control. H1RO was measured using positron emission tomography (PET) with C-11-doxepin in 12 of the 20 subjects, and a further 11 volunteers were recruited to act as controls. In psychomotor tests, fexofenadine was not significantly different from placebo and significantly less impairing than cetirizine on some tasks, as well as significantly less impairing than hydroxyzine on all tasks. For subjective sleepiness, fexofenadine was not significantly different from placebo, whereas cetirizine showed a trend toward increased sleepiness compared with fexofenadine and placebo. H1RO was negligible with fexofenadine (-0.1%) but moderately high with cetirizine (26.0%). In conclusion, fexofenadine 120 mg is distinguishable from cetirizine 20 mg, as assessed by H1RO and psychomotor testing.

  109. 加齢ラットにおける[11C]donepezilの結合特性の評価

    船木善仁, 加藤元久, 岩田錬, 谷内一彦

    日本薬学会年会要旨集 124年会 (3) 66-66 2004年3月

  110. [F-18]TAK-147, a potential radiotracer for imaging acetylcholinesterase: Radiochemical synthesis and binding characteristics in rat brain 査読有り

    M Kato, Y Funaki, Y Ishikawa, R Iwata, K Yanai

    JOURNAL OF PHARMACOLOGICAL SCIENCES 94 (1) 166P-166P 2004年

    出版者・発行元:JAPANESE PHARMACOLOGICAL SOC

    ISSN:1347-8613

  111. Decreased striatal D-2 receptor density associated with severe behavioral abnormality in Alzheimer's disease 査読有り

    Y Tanaka, K Meguro, S Yamaguchi, H Ishii, S Watanuki, Y Funaki, K Yamaguchi, A Yamadori, R Iwata, M Itoh

    ANNALS OF NUCLEAR MEDICINE 17 (7) 567-573 2003年10月

    出版者・発行元:JAPANESE SOCIETY NUCLEAR MEDICINE

    ISSN:0914-7187

    詳細を見る 詳細を閉じる

    Objectives: Since patients manifesting behavioral and psychological symptoms of dementia (BPSD) are a burden for their families and caregivers, the underlying neurobiological mechanism of this condition should be clarified. Using positron emission tomography (PET), we previously reported that wandering behavior in dementia was associated with a disturbed dopaminergic neuron system. We herein investigated the relationship between the severity of BPSD and the striatal D-2 receptor density in Alzheimer's disease (AD). Methods: Ten patients with probable AD as per the National Institute of Neurological and Communicative Disorders and Stroke (NINCDS) and the AD and Related Disorders Association (ADRDA) criteria and five normal subjects were examined with PET. The tracer used was [C-11]raclopride (D-2 antagonist). The uptake of [C-11]raclopride was calculated as the estimation of binding potential (BP) of the striatum to the cerebellum. The AD patients were institutionalized in multiple nursing homes, and their BPSD were evaluated by the Behavioral Pathology in AD Frequency Weighted Severity Scale (BEHAVE-AD-FW) scale (Reisberg). Results: There was a significant inverse Spearman's correlation between BEHAVE-AD-FW score and the BP, especially between the score of the behavioral domain and the BP values. The BP was found to be lower in severer BPSD patients. Conclusions: Patients with AD who manifest severe BPSD may have some dysfunction of striatal dopamine metabolism compared with those without BPSD.

  112. Dynamic positron autoradiography法による[11C]donepezilの結合特性の検討

    船木善仁, 加藤元久, 岩田錬, 谷内一彦

    核医学 40 (3) 380-380 2003年8月

  113. Dynamic positron autoradiography法を用いた[11C]donepezilの結合特性の評価

    船木善仁, 加藤元久, 岩田錬, 井戸達雄, 谷内一彦

    日本薬学会年会要旨集 123年会 (3) 68-68 2003年3月

  114. Evaluation of the binding characteristics of [5-C-11-methoxy]Donepezil in the rat brain for in vivo visualization of acetylcholinesterase 査読有り

    Y Funaki, M Kato, R Iwata, E Sakurai, E Sakurai, M Tashiro, T Ido, K Yanai

    JOURNAL OF PHARMACOLOGICAL SCIENCES 91 (2) 105-112 2003年2月

    出版者・発行元:JAPANESE PHARMACOLOGICAL SOC

    DOI: 10.1254/jphs.91.105  

    ISSN:1347-8613

    詳細を見る 詳細を閉じる

    Donepezil, an acetylcholinesterase (AChE) inhibitor, has not been evaluated for its binding characteristics using a radioactive tracer, although its inhibitory action on AChE has been studied. The aim of this research is to examine whether AChE can be visualized in vivo and in vitro with [C-11]donepezil. [5-C-11-methoxy]Donepezil was synthesized by O-methylation using [C-11]methyl triflate. The binding of [C-11]donepezil to brain homogenates was higher in the brain stem and striatum, and it was lowest in the cerebellum. The in vitro autoradiographic study successfully demonstrated the specific binding of [C-11]donepezil to AChE in the rat brain. The IC50 value of binding was approximately 10 nM, which is comparable to the reported value for inhibiting enzyme activity (6 nM). Saturation experiments revealed that the B-max and K-d of [C-11]donepezil binding in vitro are 65 fmol/mg tissue and 39.8 nM, respectively. In accordance with the in vitro bindings, the in vivo distribution of [C-11]donepezil was heterogeneous in the rat brain. In the blocking experiments, the heterogeneous distribution disappeared in the presence of a large amount of unlabeled donepezil. These data suggest that [5-C-11-methoxy]donepezil can be potentially useful to image AChE non-invasively in the human brain by positron emission tomography.

  115. Sedative profiles of second-generation antihistamines.

    Tashiro M, Iwabuchi K, Sakurada Y, Mochizuki H, Kato M, Horikawa E, Funaki Y, Iwata R, Itoh M, Yanai K

    CYRIC Annual Report 2003 185-191 2003年

    出版者・発行元:Cyclotron and Radioisotope Center, Tohoku University

    詳細を見る 詳細を閉じる

    CYRIC Annual Report 2003

  116. The binding characteristics in rat brain using in vivo bioradiography with [C-11]donepezil, a radiotracer for acetylcholinesterase. 査読有り

    M Kato, Y Funaki, R Iwata, K Yanai

    JOURNAL OF PHARMACOLOGICAL SCIENCES 91 (1) 180P-180P 2003年

    出版者・発行元:JAPANESE PHARMACOLOGICAL SOC

    ISSN:1347-8613

  117. [11C]クロバザムの合成とその生物学的動態の検討

    船木善仁, 岩田錬, 井戸達雄, 谷内一彦

    核医学 39 (3) 406-406 2002年9月

  118. [11C]Donepezilの合成とPET薬剤としての基礎的検討

    船木善仁, 加藤元久, 岩田錬, 井戸達雄, 谷内一彦

    日本薬学会年会要旨集 122年会 (3) 65-65 2002年3月

  119. Biological evaluation of [5-11C-methoxy]donepezil in the rat brain.

    Funaki Y, Kato M, Iwata R, Sakurai E, Sakurai E, Tashiro M, Ido T, Yanai K

    CYRIC Annual Report 2002 83-86 2002年

    出版者・発行元:Cyclotron and Radioisotope Center, Tohoku University

    詳細を見る 詳細を閉じる

    CYRIC Annual Report 2002

  120. [11C]ドネペジルの臨床応用を目的とした基礎的検討

    船木善仁, 加藤元久, 岩田錬, 井戸達雄, 谷内一彦

    核医学 38 (5) 591-591 2001年9月

  121. Influence of anesthesia on brain distribution of [C-11]methamphetamine in monkeys in positron emission tomography (PET) study 査読有り

    M Mizugaki, N Nakagawa, H Nakamura, T Hishinuma, Y Tomioka, S Ishiwata, T Ido, R Iwata, Y Funaki, M Itoh, M Higuchi, N Okamura, T Fujiwara, M Sato, K Shindo, S Yoshida

    BRAIN RESEARCH 911 (2) 173-175 2001年8月

    出版者・発行元:ELSEVIER SCIENCE BV

    DOI: 10.1016/S0006-8993(01)02669-5  

    ISSN:0006-8993

    詳細を見る 詳細を閉じる

    We investigated the influence of anesthesia on the brain distribution of [C-11]methamphetamine (MAP) obtained by the positron emission tomography (PET) using the normal rhesus monkeys. We clarified that the brain uptake of [C-11]MAP under halothane anesthesia was faster and higher than that under pentobarbital. The difference of the effect of anesthesia is an important problem in pharmacokinetic study in PET with experimental animals. (C) 2001 Elsevier Science B.V. All rights reserved.

  122. アセチルコリンエステラーゼ阻害剤Donepezilの11C-標識化とその結合評価

    加藤元久, 船木善仁, 岩田錬, 櫻井栄一, 櫻井映子, 谷内一彦

    日本薬理学雑誌 119 (1) 20P-20P 2001年1月

  123. 放射線治療:中性子捕捉療法(NCT)とは? 査読有り

    船木 善仁

    ファルマシア 30 (1) 54-54 2000年

    出版者・発行元:公益社団法人日本薬学会

    ISSN:0014-8601

  124. 神経伝達機能の定量化に及ぼす生理的因子の解明に関する研究

    井戸達雄, 岩田錬, 船木善仁, 佐々木進, 中川直人, 初鹿稔, 谷内一彦, 藤原竹彦

    厚生省精神・神経疾患研究委託費研究報告書 機能的画像診断による精神・神経疾患の総合的研究 平成6.7.8年度 57-61 1997年3月

  125. Effects of haloperidol and cocaine pretreatments on brain distribution and kinetics of [C-11]methamphetamine in methamphetamine sensitized dog: Application of PET to drug pharmacokinetic study 査読有り

    H Nakamura, T Hishinuma, Y Tomioka, S Ishiwata, T Ido, R Iwata, Y Funaki, M Itoh, T Fujiwara, K Yanai, M Sato, Y Numachi, S Yoshida, M Mizugaki

    NUCLEAR MEDICINE AND BIOLOGY 24 (2) 165-169 1997年2月

    出版者・発行元:PERGAMON-ELSEVIER SCIENCE LTD

    DOI: 10.1016/S0969-8051(96)00204-1  

    ISSN:0883-2897

    詳細を見る 詳細を閉じる

    Repeated administration of methamphetamine (MAP) causes behavioral sensitization in animals. We previously reported that the maximum accumulation level of [C-11]MAP in the MAP sensitized dog brain was 1.4 times higher than that in the control. In behavioral studies, haloperidol (a dopamine D-2 receptor antagonist) prevents MAP induced behavioral sensitization, and cocaine (a dopamine reuptake blocker) has the cross-behavioral sensitization with MAP. In the present study, to elucidate the relation between the MAP induced behavioral sensitization and the pharmacokinetics of MAP, we investigated the effects of haloperidol and cocaine pretreatments on brain regional distribution and kinetics of [C-11]MAP using positron emission tomography (PET). A significant increase of [C-11]MAP uptake into the sensitized dog brain was prevented by haloperidol and cocaine pretreatments. These pharmacokinetic changes were not due to the changes in the rate of MAP metabolism. These results suggest haloperidol and cocaine can change the cerebral pharmacokinetic profile of MAP in the behavioral-sensitized dog. The variations of MAP-accumuation may affect the development or expression of MAP-induced behavioral sensitization. (C) 1997 Elsevier Science Inc.

  126. Characterization of a new breast cancer-associated antigen and its relationship to MUC1 and TAG-72 antigens 査読有り

    Yuko Harada, Nobiaki Ohuchi, Takashi Masuko, Yoshihito Funaki, Shozo Mori, Susumu Satomi, Yoshiyuki Hashimoto

    Tohoku Journal of Experimental Medicine 180 (3) 273-288 1996年

    出版者・発行元:Tohoku University Medical Press

    DOI: 10.1620/tjem.180.273  

    ISSN:0040-8727

    詳細を見る 詳細を閉じる

    We have characterized a new tumor-associated antigen defined by monoclonal antibody (MAb) generated against HMA-1 breast cancer cell line. MAb AM-1 was selected based on its preferential reactivity to breast cancer cells versus to normal or benign epithelial cells by immunofluorescence and immunohistochemical assays of cultured, or fresh specimens. AM-1 demonstrated strong reactivity to breast cancer cell lines including HMA-1, YMB-1-E, YMB-1 and MDA-MB-231 in flow cytometry. In immunoprecipitation, AM-1 recognized high molecular weight components of 160-210 kDa and &gt 370 kDa. Reactivity with HMA-1 cells was diminished markedly when treated by heat, protease or periodate, suggesting that the antigenic epitope is composed with carbohydrates and peptides. Enzyme digestion of precipitated antigens demonstrated that the antigen contains O-linked and N-linked carbohydrates with neuraminic acid structures. Furthermore, binding inhibition and sandwich ELISA assays using MAbs reactive with known breast cancer-associated antigens and synthetic MUC1 core peptide (PDTRPAPGSTAPPAHGVTSAPDTR) demonstrated that the antigen is distinct from CEA, TAG-72 or MUC1, while the antigen conjoins with MUC1 and TAG-72 as a trimmer form in HMA-1 cells. These results suggest that AM-1 recognizes a novel glycoprotein which is abundant in breast cancer, and may be utilized in the management of breast cancer patients.

  127. Positron emission tomography study of the alterations in brain distribution of [C-11]methamphetamine in methamphetamine-sensitized dog 査読有り

    H Nakamura, T Hishinuma, Y Tomioka, T Ido, R Iwata, Y Funaki, M Itoh, T Fujiwara, K Yanai, M Sato, Y Numachi, S Yoshida, M Mizugaki

    CELLULAR AND MOLECULAR MECHANISMS OF DRUGS OF ABUSE 801 401-408 1996年

    出版者・発行元:NEW YORK ACAD SCIENCES

    DOI: 10.1111/j.1749-6632.1996.tb17462.x  

    ISSN:0077-8923

  128. POSITRON EMISSION TOMOGRAPHY (PET) STUDY OF THE ALTERATIONS IN BRAIN DISTRIBUTION OF [C-11] METHAMPHETAMINE IN METHAMPHETAMINE SENSITIZED DOG 査読有り

    M MIZUGAKI, H NAKAMURA, T HISHINUMA, Y TOMIOKA, S ISHIWATA, H SUZUKI, T IDO, R IWATA, Y FUNAKI, M ITOH, T FUJIWARA, K YANAI, M SATO, Y NUMACHI, S YOSHIDA

    NUCLEAR MEDICINE AND BIOLOGY 22 (6) 803-807 1995年8月

    出版者・発行元:PERGAMON-ELSEVIER SCIENCE LTD

    DOI: 10.1016/0969-8051(95)00025-S  

    ISSN:0883-2897

    詳細を見る 詳細を閉じる

    [C-11]Methamphetamine ([C-11]MAP) was synthesized by an automated on-line [C-11]methylation system for positron emission tomography (PET) study. We newly produced a MAP sensitized dog by repeated MAP treatment and studied the brain distribution of [C-11]MAP in the normal and the MAP sensitized dog. The maximal level of accumulation of [C-11]MAP in the sensitized dog brain was 1.4 times higher than that in the control. No difference was found in the metabolism of MAP between the two conditions. The significant increase of [C-11]MAP in the MAP sensitized brain indicates that subchronic MAP administration causes some functional change in uptake site of MAP.

  129. Positron emission tomography (PET) study of the alterations in brain distribution of [11C]methamphetamine in methamphetamine sensitized dog 査読有り

    Michinao Mizugaki, Hitoshi Nakamura, Takanori Hishinuma, Yoshihisa Tomioka, Shunji Ishiwata, Hideaki Suzuki, Tatsuo Ido, Ren Iwata, Yoshihito Funaki, Masatoshi Itoh, Takehiko Fujiwara, Kazuhiko Yanai, Mitsumoto Sato, Yohtaro Numachi, Sumiko Yoshida

    Nuclear Medicine and Biology 22 (6) 803-807 1995年

    DOI: 10.1016/0969-8051(95)00025-S  

    ISSN:0969-8051

    詳細を見る 詳細を閉じる

    [11C]Methamphetamine ([11C]MAP) was synthesized by an automated on-line [11C]methylation system for positron emission tomography (PET) study. We newly produced a MAP sensitized dog by repeated MAP treatment and studied the brain distribution of [11C]MAP in the normal and the MAP sensitized dog. The maximal level of accumulation of [11C]MAP in the sensitized dog brain was 1.4 times higher than that in the control. No difference was found in the metabolism of MAP between the two conditions. The significant increase of [11C]MAP in the MAP sensitized brain indicates that subchronic MAP administration causes some functional change in uptake site of MAP. © 1995.

  130. Preparation of [<SUP>11</SUP>C]caffeines from [<SUP>11</SUP>C]methyl iodide.

    Yoshihito Funaki

    CYRIC ANNUAL REPORT 1992 1992 103-105 1993年10月

    出版者・発行元:Cyclotron and Radioisotope Center, Tohoku University

    詳細を見る 詳細を閉じる

    開始ページ、終了ページ: 冊子体のページ付け

  131. カフェインの脳神経伝達系への影響 査読有り

    船木 善仁

    微量栄養素研究第10集 171 1993年

  132. 神経伝達物質に対するカフェインの影響-マイクロダイアリシス法を応用したin vivoでの測定 査読有り

    船木 善仁

    微量栄養素研究第9集 47 1992年

︎全件表示 ︎最初の5件までを表示

MISC 61

  1. LOOP-SPE法を用いた[11C]metomidateの合成

    船木 善仁, 石川 洋一, 岩田 錬, 谷内 一彦

    核医学 55 (Suppl.) S229-S229 2018年11月

    出版者・発行元:(一社)日本核医学会

    ISSN:0022-7854

    eISSN:2189-9932

  2. ラットPETを用いたヒト内部被曝線量の非侵襲的推定手法の検討

    志田原 美保, 猪又 嵩斗, 小山 千莉, 船木 善仁, 田代 学, 古本 祥三, 谷内 一彦, 権田 幸祐, 渡部 浩司

    核医学 54 (Suppl.) S199-S199 2017年9月

    出版者・発行元:(一社)日本核医学会

    ISSN:0022-7854

  3. 18F-FDG PETを用いた冠動脈周囲脂肪組織の炎症性変化の検討 薬剤溶出性ステント留置後のブタ冠動脈過収縮モデルを用いて

    大山 宗馬, 松本 泰治, 天水 宏和, 宇塚 裕紀, 西宮 健介, 諸沢 薦, 平野 道基, 渡部 浩司, 船木 善仁, 高橋 潤, 伊藤 健太, 下川 弘明

    日本心臓核医学会ニュースレター 19 (2) 15-16 2017年6月

    出版者・発行元:日本心臓核医学会

    ISSN:1346-2733

  4. Evidence for Involvement of Inflammatory Changes of Perivascular Adipose Tissue in the Pathogenesis of Coronary Hyperconstricting Responses Induced by Drug-Eluting Stent in Pigs in vivo - Impact of Fluorodeoxyglucose Positron Emission Tomography Imaging

    Kazuma Ohyama, Yasuharu Matsumoto, Hirokazu Amamizu, Hironori Uzuka, Kensuke Nishimiya, Susumu Morosawa, Michinori Hirano, Hiroshi Watabe, Yoshihito Funaki, Jun Takahashi, Kenta Ito, Hiroaki Shimokawa

    CIRCULATION 134 2016年11月

    出版者・発行元:LIPPINCOTT WILLIAMS & WILKINS

    ISSN:0009-7322

    eISSN:1524-4539

  5. Evidence for Involvement of Inflammatory Changes of Perivascular Adipose Tissue in the Pathogenesis of Coronary Hyperconstricting Responses Induced by Drug-Eluting Stent in Pigs in vivo -Impact of Fluorodeoxyglucose Positron Emission Tomography Imaging

    Kazuma Ohyama, Yasuharu Matsumoto, Hirokazu Amamizu, Hironori Uzuka, Kensuke Nishimiya, Susumu Morosawa, Michinori Hirano, Hiroshi Watabe, Yoshihito Funaki, Jun Takahashi, Kenta Ito, Hiroaki Shimokawa

    CIRCULATION 134 2016年11月

    出版者・発行元:LIPPINCOTT WILLIAMS & WILKINS

    ISSN:0009-7322

    eISSN:1524-4539

  6. Renal denervation suppresses coronary hyperconstricting responses after DES implantation in pigs in vivo - evidence for the kidney-brain-heart interactions

    H. Uzuka, Y. Matsumoto, K. Ohyama, K. Nishimiya, H. Amamizu, S. Morosawa, M. Hirano, K. Hao, R. Tsuburaya, K. Ito, J. Takahashi, Y. Funaki, H. Watabe, H. Shimokawa

    EUROPEAN HEART JOURNAL 37 1003-1004 2016年8月

    出版者・発行元:OXFORD UNIV PRESS

    ISSN:0195-668X

    eISSN:1522-9645

  7. Evidence for involvement of inflammatory changes of perivascular adipose tissue in the pathogenesis of DES-induced hyperconstricting responses in pigs in vivo - impact of 18F-FDG PET imaging

    K. Ohyama, Y. Matsumoto, H. Amamizu, H. Uzuka, K. Nishimiya, S. Morosawa, M. Hirano, H. Watabe, Y. Funaki, J. Takahashi, K. Ito, H. Shimokawa

    EUROPEAN HEART JOURNAL 37 786-786 2016年8月

    出版者・発行元:OXFORD UNIV PRESS

    ISSN:0195-668X

    eISSN:1522-9645

  8. メチルトリフレートを用いたオンカラムメチオニン合成における放射化学的純度の変化

    船木 善仁, 林 緑也, 石川 洋一, 岩田 錬, 谷内 一彦

    核医学 52 (3) 289-289 2015年9月

    出版者・発行元:(一社)日本核医学会

    ISSN:0022-7854

  9. Longitudinal [C-11]BF-227 PET study in MSA-C patients

    A. Kikuchi, N. Okamura, M. Tashiro, S. Furumoto, T. Hasegawa, S. Watanuki, K. Hiraoka, Y. Funaki, T. Baba, M. Kobayashi, N. Sugeno, M. Konno, E. Miura, R. Oshima, S. Yoshida, R. Iwata, S. Takahashi, H. Fukuda, Y. Itoyama, H. Arai, Y. Kudo, K. Yanai, M. Aoki, A. Takeda

    MOVEMENT DISORDERS 30 S383-S383 2015年6月

    出版者・発行元:WILEY-BLACKWELL

    ISSN:0885-3185

    eISSN:1531-8257

  10. PETによる新規抗精神病薬(オランザピン・クエチアピン)のヒト脳内H1受容体占拠率の解析

    佐藤博俊, 伊藤千裕, 平岡宏太良, 田代学, 渋谷勝彦, 船木善仁, 吉川雄朗, 岩田錬, 松岡洋夫, 谷内一彦, 谷内一彦

    日本臨床精神神経薬理学会プログラム・抄録集 25th 2015年

  11. Measurement of Free Fraction in Plasma for Biomathematical Prediction of SUVR of Amyloid PET Radiotracers

    Nai Y.-H., Shidahara M., Seki C., Watanuki S., Funaki Y., Ishikawa Y., Furumoto S., Watabe H.

    CYRIC annual report 2014 73-77 2015年

    出版者・発行元:Cyclotron and Radioisotope Center, Tohoku University

  12. Longitudinal Assessment of Tau Pathology in Patients with Alzheimer's Disease Using [18F]THK-5117 Positron Emission Tomography

    Ishiki A., Okamura N., Furukawa K., Furumoto S., Harada R., Tomita N., Hiraoka K., Watanuki S., Ishikawa Y., Funaki Y., Iwata R., Tashiro M., Yanai K., Kudo Y., Arai H.

    CYRIC annual report 2014 79-81 2015年

    出版者・発行元:Cyclotron and Radioisotope Center, Tohoku University

  13. In vivo visualization of alpha-synuclein deposition by carbon-11-labeled 2-(2-[2-dimethylaminothiazol-5-yl]ethenyl)-6-(2-[fluoro]ethoxy)benzoxazole positron emission tomography in Parkinson's disease

    A. Kikuchi, N. Okamura, M. Tashiro, T. Hasegawa, N. Sugeno, T. Baba, M. Konno, E. Miura, R. Oshima, S. Furumoto, Y. Funaki, R. Iwata, S. Takahashi, H. Fukuda, H. Arai, Y. Kudo, K. Yanai, Y. Itoyama, M. Aoki, A. Takeda

    MOVEMENT DISORDERS 29 S77-S77 2014年5月

    出版者・発行元:WILEY-BLACKWELL

    ISSN:0885-3185

    eISSN:1531-8257

  14. タウイメージング薬剤[18F]THK-5117を用いたPET臨床試験(速報)

    田代 学, 岡村 信行, 古本 祥三, 四月朔日, 聖一, 平岡 宏太良, 古川 勝敏, 志田原 美保, 石木 愛子, 冨田 尚希, 松田 林, 稲見 暁惠, 武田 和子, 三宅 正泰, 船木 善仁, 岩田 錬, 工藤 幸司, 荒井 啓行, 谷内 一彦

    核医学 51 (1) 28-28 2014年2月

    出版者・発行元:(一社)日本核医学会

    ISSN:0022-7854

    eISSN:2189-9932

  15. フッ素標識アミロイドイメージング薬剤[18F]FACTの動態解析

    田代 学, 岡村 信行, 古本 祥三, 四月朔日, 聖一, 平岡 宏太良, 古川 勝敏, 志田原 美保, 三宅 正泰, 船木 善仁, 岩田 錬, 工藤 幸司, 荒井 啓行, 谷内 一彦

    核医学 50 (2) 70-70 2013年5月

    出版者・発行元:(一社)日本核医学会

    ISSN:0022-7854

    eISSN:2189-9932

  16. 血流遮断により誘発された腫瘍内元素動態分析へのPIXE法の応用

    寺川貴樹, 石井慶造, 松山成男, 菊池洋平, 草野薫, 菅井裕之, 唐橋昌宏, 能澤雄一郎, 山崎浩道, 船木善仁, 古本祥三, 伊藤伸彦, 和田成一

    日本原子力学会秋の大会予稿集(CD-ROM) 2013 2013年

  17. アミロイドイメージングを用いたアルツハイマー病発症リスク予測法の実用化に関する多施設臨床研究 <sup>11</sup>C-BF-227PETを用いたLewy小体型認知症の臨床評価

    田代学, 岡村信行, 古川勝敏, 古本祥三, 古本祥三, 冨田尚希, 菊池昭夫, 平岡宏太良, 船木善仁, 四月朔日聖一, 三宅正泰, 武田篤, 岩田錬, 工藤幸司, 荒井啓行, 谷内一彦, 谷内一彦

    アミロイドイメージングを用いたアルツハイマー病発症リスク予測法の実用化に関する多施設臨床研究 平成24年度 総括・分担研究報告書 2013年

  18. 小動物PET/CTを用いた抗ヒスタミン薬レボセチリジンの鎮静性評価

    飯田 智光, 船木 善仁, 石渡 喜一, 長沼 史登, 原田 龍一, 吉川 雄朗, 古本 祥三, 岩田 錬, 谷内 一彦

    日本薬理学雑誌 141 (1) 3P-3P 2013年1月

    出版者・発行元:(公社)日本薬理学会

    ISSN:0015-5691

    eISSN:1347-8397

  19. [5-11C-methoxy]donepezilとPETを用いたアセチルコリンエステラーゼに対するドネペジルの結合の定量解析

    平岡 宏太良, 四月朔日, 聖一, 田代 学, 岡村 信行, 谷内 一彦, 船木 善仁, 森 悦朗, 渡部 浩司

    Japanese Journal of Radiology 30 (Suppl.I) 15-15 2012年2月

    出版者・発行元:(公社)日本医学放射線学会

    ISSN:1867-1071

    eISSN:1867-108X

  20. アミロイドイメージングを用いたアルツハイマー病発症リスク予測法の実用化に関する多施設臨床研究[<sup>18</sup>F]FACTを用いたアルツハイマー病診断における定量法の検討

    田代学, 志田原美保, 志田原美保, 岡村信行, 古川勝敏, 古本祥三, 古本祥三, 平岡宏太良, 船木善仁, 四月朔日聖一, 三宅正泰, 冨田尚希, 石川洋一, 岩田錬, 田村元, 工藤幸司, 荒井啓行, 谷内一彦, 谷内一彦

    アミロイドイメージングを用いたアルツハイマー病発症リスク予測法の実用化に関する多施設臨床研究 平成23年度 総括・分担研究報告書 2012年

  21. 認知障害を伴うパーキンソン病におけるdonepezilのアセチルコリンエステラーゼに対する結合 [5-11C-methoxy]donepezilを用いたPET研究

    平岡 宏太良, 岡村 信行, 船木 善仁, 四月朔日 聖一, 田代 学, 加藤 元久, 林 亜希子, 山崎 浩, 西尾 慶之, 久永 欣哉, 藤井 俊勝, 武田 篤, 谷内 一彦, 森 悦朗

    臨床神経学 51 (12) 1205-1205 2011年12月

    出版者・発行元:(一社)日本神経学会

    ISSN:0009-918X

    eISSN:1882-0654

  22. [5-11C-methoxy]donepezilとPETを用いたアセチルコリンエステラーゼに対するドネペジルの結合の定量解析

    平岡 宏太郎, 岡村 信行, 船木 善仁, 四月朔日 聖一, 田代 学, 森 悦朗, 谷内 一彦, 渡部 浩司

    核医学 48 (4) 438-438 2011年11月

    出版者・発行元:(一社)日本核医学会

    ISSN:0022-7854

    eISSN:2189-9932

  23. PETによる新規抗うつ薬(NaSSA・SSRI)のヒト脳内H1受容体占拠率の解析

    佐藤 博俊, 伊藤 千裕, 田代 学, 渋谷 勝彦, 張 冬頴, 平岡 宏太良, 船木 善仁, 岩田 錬, 谷内 一彦, 松岡 洋夫

    日本臨床精神神経薬理学会・日本神経精神薬理学会合同年会プログラム・抄録集 21回・41回 165-165 2011年10月

    出版者・発行元:日本臨床精神神経薬理学会・日本神経精神薬理学会

  24. 分子イメージング法を用いた創薬科学 薬物副作用と疾患病態研究

    田代学, 谷内一彦, 岡村信行, 古本祥三, 張冬頴, 渋谷勝彦, 福土審, 金澤素, 鹿野理子, 森下城, 田中由佳里, 武田篤, 菊池昭夫, 松岡洋夫, 伊藤千裕, 佐藤博俊, 井樋栄二, 佐野博高, 岸本光司, 柏葉光宏, 近江礼, 篠崎晋久, 黒川大介, 古川勝敏, 冨田尚樹, 荒井啓行, 藤本敏彦, 関隆志, 工藤幸司, 堂浦克美, 吉岡孝志, 堀川悦夫, 伊藤正敏, 山口慶一郎, 岩田錬, 船木善仁, 石川洋一, 平岡宏太良, 四月朔日聖一, 三宅正泰, マスド・メヘディ, 小倉毅, 武田和子, 馬場護, 石井慶造

    臨床薬理 42 (4) 245-252 2011年7月

    出版者・発行元:(一社)日本臨床薬理学会

    DOI: 10.3999/jscpt.42.245  

    ISSN:0388-1601

    eISSN:1882-8272

  25. アミロイド・イメージングを用いたアルツハイマー病の発症・進展予測法の実用化に関する多施設大規模臨床研究[C-11]BF-227 PETを用いた認知症の臨床評価

    田代学, 岡村信行, 古川勝敏, 古本祥三, 古本祥三, 菊池昭夫, 平岡宏太良, 船木善仁, 四月朔日聖一, 三宅正泰, 武田篤, 岩田錬, 堂浦克美, 糸山泰人, 工藤幸司, 荒井啓行, 谷内一彦, 谷内一彦

    アミロイドイメージングを用いたアルツハイマー病の発症・進展予測法の実用化に関する多施設大規模臨床研究 平成22年度 総括・分担研究報告書 2011年

  26. 薬物脳内移行性のPETによる測定 抗ヒスタミン薬を例に

    谷内 一彦, 張 冬穎, 原田 龍一, 中村 正帆, 吉川 雄朗, 船木 善仁, 渋谷 勝彦, 古本 祥三, 田代 学, 岩田 錬, 岡村 信行

    ナノ医工学年報 4 (1) 119-122 2011年

    出版者・発行元:東北大学グローバルCOEプログラム「新世紀世界の成長焦点に築くナノ医工学拠点」

    ISSN:1882-4692

  27. アルツハイマー病早期診断のための脳アミロイド・イメージング薬剤[11C]BF-227および[18F]FACTの動態解析 (臨床薬理)

    田代学, 岡村信行, 古本祥三, 四月朔日聖一, 船木善仁, 岩田錬, 工藤幸司, 古川勝敏, 荒井啓行, 谷内一彦

    臨床薬理 41 (Suppl.) S206-S206 2010年11月

  28. 腫瘍血管遮断剤AVE8062による陽子線治療の増感に関する基礎研究

    寺川貴樹, 石井慶造, 松山成男, 菊池洋平, 秋山久樹, 小屋田寛, 伊藤友紀, 田川篤志, 康永盛欽, 山崎浩道, 田代学, 船木善仁, 古本祥三, 伊藤伸彦, 和田成一

    日本原子力学会秋の大会予稿集(CD-ROM) 2010 2010年

  29. シスプラチンを併用した陽子線治療効果の基礎研究

    伊藤友紀, 寺川貴樹, 石井慶造, 松山成男, 菊池洋平, 田川篤志, 康永盛欽, 羽鳥悦脩, 浜田尚希, 藤木広太, 山崎浩道, 船木善仁, 世良耕一郎, 伊藤伸彦, 和田成一

    日本原子力学会秋の大会予稿集(CD-ROM) 2010 2010年

  30. アミロイドイメージングを用いたアルツハイマー病の発症・進展予測法の実用化に関する多施設大規模臨床研究[C-11]BF-227を用いたアルツハイマー病診断における定量法の検討

    田代学, 岡村信行, 古川勝敏, 古本祥三, 古本祥三, 熊谷和明, 藁谷正明, 船木善仁, 四月朔日聖一, 三宅正泰, 岩田錬, 工藤幸司, 荒井啓行, 谷内一彦, 谷内一彦

    アミロイドイメージングを用いたアルツハイマー病の発症・進展予測法の実用化に関する多施設大規模臨床研究 平成21年度 総括・分担研究報告書 2010年

  31. Evaluation of I-124 as a nuclide for PET radioligand with I-124-iomazenil and imaging of rat brain by means of semiconductor high resolution animal PET scanner.

    Y. Kanai, Y. Funaki, H. Yamazaki, Y. Kikuchi, S. Matsuyama, M. Imaizumi, E. Shimosegawa, K. Ishii, J. Hatazawa

    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING 36 S398-S398 2009年9月

    出版者・発行元:SPRINGER

    ISSN:1619-7070

  32. [F-18]FACT PET is Useful for Noninvasive Detection of Amyloid Plaques in Alzheimer's Disease

    K. Sugi, N. Okamura, S. Furumoto, M. Tashiro, K. Furukawa, Y. Funaki, H. Arai, Y. Kudo, R. Iwata, K. Yanai

    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING 36 S379-S379 2009年9月

    出版者・発行元:SPRINGER

    ISSN:1619-7070

  33. [C-11]BF-227 PET Study in Protein Conformational Diseases

    N. Okamura, S. Furumoto, M. Tashiro, Y. Funaki, A. Kikuchi, Y. Shiga, K. Furukawa, H. Arai, K. Doh-ura, R. Iwata, K. Yanai, Y. Kudo

    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING 36 S379-S379 2009年9月

    出版者・発行元:SPRINGER

    ISSN:1619-7070

  34. 粒子線治療効果を上げるための抗がん剤のがん細胞への集積度の研究

    伊藤友紀, 石井慶造, 寺川貴樹, 松山成男, 菊池洋平, 藤原充啓, 川村悠, 大倉曉, 藤川誠, 羽鳥悦脩, 濱田尚希, 藤木広太, 山崎浩道, 船木善仁, 橋本悠太郎

    日本原子力学会秋の大会予稿集(CD-ROM) 2009 2009年

  35. PETを用いた多施設共同臨床試験によるアルツハイマー病の超早期診断法の確立と普及 簡易定量法の開発を目的としたBF-227の生体内動態解析

    田代学, 岡村信行, 熊谷和明, 古本祥三, 古川勝敏, 藁谷正明, 船木善仁, 四月朔日聖一, 三宅正泰, 岩田錬, 工藤幸司, 荒井啓行, 木村裕一, 渡部浩司, 谷内一彦

    PETを用いた多施設共同臨床試験によるアルツハイマー病の超早期診断法の確立と普及 平成20年度 総括研究報告書 総合研究報告書 2009年

  36. アミロイドイメージングを用いたアルツハイマー病の発症・進展予測法の実用化に関する多施設大規模臨床研究[C-11]BF-227を用いたアルツハイマー病および軽度認知障害の早期診断法

    田代学, 岡村信行, 熊谷和明, 古本祥三, 古川勝敏, 藁谷正明, 船木善仁, 四月朔日聖一, 三宅正泰, 岩田錬, 工藤幸司, 荒井啓行, 谷内一彦

    アミロイドイメージングを用いたアルツハイマー病の発症・進展予測法の実用化に関する多施設大規模臨床研究 平成20年度 総括・分担研究報告書 2009年

  37. 腫瘍血管遮断剤AVE8062を併用した陽子線照射の抗腫瘍効果に関する研究

    寺川貴樹, 石井慶造, ESMAILI-TORSHABI Ahmad, 千葉俊行, 宮下拓也, 山本竜也, 有川潤, 富樫貴紀, 山下航, 秋山久樹, 小屋田寛, 山崎浩道, 田代学, 船木善仁, 古本祥三, 伊藤伸彦, 和田成一

    日本原子力学会秋の大会予稿集(CD-ROM) 2008 2008年

  38. Delivery of Na/I Symporter Gene into Skeletal Muscle by Using Nanobubbles and Ultrasound: Visualization of Gene Expression with PET

    Watanabe Y., Horie S., Funaki Y., Kikuchi Y., Yamazaki H., Ishii K., Vassaux G., Mori S., Kodama T.

    CYRIC annual report 2008 142-147 2008年

    出版者・発行元:Cyclotron and Radioisotope Center, Tohoku University

  39. Radiosynthesis of [124I]Iomazenil and Imaging of Rat Brain by Means of Semiconductor High Resolution Animal PET Scanner

    Kanai Y., Yamazaki H., Funaki Y., Matsuyama S., Kikuchi Y., Sakamaki M., Shimosegawa E., Ishii K., Hatazawa J.

    CYRIC annual report 2008 137-141 2008年

    出版者・発行元:Cyclotron and Radioisotope Center, Tohoku University

  40. Synthesis of Iodine-124 Labeled αEGF-R Antibody and its Biological Evaluation

    Horiuchi Y, Funaki Y, Kikuchi Y, Yamazaki H, Ishii K

    CYRIC annual report 2007 77-80 2007年

    出版者・発行元:Cyclotron and Radioisotope Center, Tohoku University

  41. Decreased Binding of[11C]Donepezil as Shown by PET Correlated with the Clinical Effect of Donepezil Administration in Alzheimer's Disease:The Osaki-Tajiri Project

    Kasuya M, Ishikawa H, Okamura N, Kato M, Sasaki Y, Nakata E, Ishikawa Y, Funaki Y, Tanaka N, Yanai K, Meguro K

    CYRIC annual report 2007 123-128 2007年

    出版者・発行元:Cyclotron and Radioisotope Center, Tohoku University

  42. 獣医療における陽子線治療の基盤的研究-東北大CYRICにおける陽子線の物理学的線量分布と生物学的影響評価-

    中澤菓, 佐野忠士, 寺川貴樹, 船木善仁, 石崎梓, 戸塚祐希, 本田泰三, 宮下拓也, 夏堀雅宏, 柿崎竹彦, 宝達崇文, 石井慶造, 佐々木伸雄, 伊藤伸彦

    日本獣医学会学術集会講演要旨集 142nd 2006年

    ISSN:1347-8621

  43. Production and Chemical Separation of "No Carrier Added" Iodine-124 from a Reusable Enriched Tellurium-124 Dioxide / Aluminum Oxide Solid Solution Target

    Yamazaki H., Funaki Y., Horiuchi Y., Ishii K., Kanai Y., Kikuchi Y., Matsuyama S.

    CYRIC annual report 2006 90-94 2006年

    出版者・発行元:Cyclotron and Radioisotope Center, Tohoku University

  44. Dynamic Human Imaging using 18F-FRP170 as a New PET Tracer for Imaging Hypoxia

    Kaneta T., Takai Y., Iwata R., Hakamatsuka T., Yasuda H., Nakayama K., Ishikawa Y., Watanuki S., Furumoto S., Funaki Y., Nakata E., Jingu K., Tsujitani M., Ito M., Fukuda H., Takahashi S., Yamada S.

    CYRIC annual report 2006 109-112 2006年

    出版者・発行元:Cyclotron and Radioisotope Center, Tohoku University

  45. Evaluation of the Binding Characteristics of [18F]Fluoroproxyfan in the Rat Brain for In Vivo Visualization of Histamine H3 Receptor

    Funaki Y., Sato K., Kato M., Ishikawa Y., Iwata R., Yanai K.

    CYRIC annual report 2006 95-100 2006年

    出版者・発行元:Cyclotron and Radioisotope Center, Tohoku University

  46. 新低酸素細胞イメージング剤[18F]FRP-170開発と臨床応用

    高井良壽, 金田朋弘, 袴塚 崇, 仲田栄子, 山田章吾, 岩田 錬, 船木善仁, 石川洋一, 辻谷典彦

    臨床放射線 51 473-484 2006年

  47. 【期待されるFDG以外の腫瘍PETイメージング製剤】新低酸素細胞イメージング剤[18F]FRP-170の開発と臨床応用

    高井 良尋, 金田 朋洋, 袴塚 崇, 仲田 栄子, 山田 章吾, 岩田 錬, 船木 善仁, 石川 洋一, 辻谷 典彦

    臨床放射線 51 (7) 837-843 2006年

    出版者・発行元:金原出版(株)

    ISSN:0009-9252

  48. PET検査用新規低酸素マーカー18F-FRP170の臨床応用

    金田 朋洋, 袴塚 崇, 高橋 昭喜, 神宮 啓一, 菅原 俊幸, 山田 章吾, 高井 良尋, 丸岡 伸, 岩田 錬, 石川 洋一, 船木 善仁, 工藤 幸司, 仲田 栄子, 古本 祥三, 福田 寛

    核医学 42 (4) 414-414 2005年12月

    出版者・発行元:(一社)日本核医学会

    ISSN:0022-7854

    eISSN:2189-9932

  49. [C-11]BF227: A New C-11-Labeled 2-Ethenylbenzoxazole Derivative for Amyloid-beta Plaques Imaging

    S. Furumoto, N. Okamura, Y. Ishikawa, M. Tashiro, M. Kato, Y. Funaki, M. Maruyama, H. Akatsu, T. Suemoto, T. Yamamoto, H. Arai, T. Sawada, R. Iwata, K. Yanai, Y. Kudo

    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING 32 S268-S268 2005年9月

    出版者・発行元:SPRINGER

    ISSN:1619-7070

  50. 低酸素細胞のPET画像化を目的とする[18F]FRP-170注射液の開発

    石川 洋一, 船木 善仁, 岩田 錬, 古本 祥三, 仲田 栄子, 工藤 幸司, 金田 朋洋, 袴塚 崇, 高井 良尋, 山田 章吾

    核医学 42 (1) 1-10 2005年

    出版者・発行元:(一社)日本核医学会

    ISSN:0022-7854

    eISSN:2189-9932

    詳細を見る 詳細を閉じる

    低酸素細胞に集積する化合物として新規に開発された[18F]FRP-170([18F]1-(2-fluoro-1-[hydroxymethyl]ethoxy)methyl-2-nitroimidazole)のPET臨床診断利用を目的にその注射液の開発を行った.再現性と信頼性の高い自動合成法を目指し,簡便なオンカラム加水分解法を導入し,液体試薬の移送と溶媒の留去に使用するHeガスの流量変化を検出することで全合成過程を自動化した.[18F]フッ素アニオンからの放射化学的収率15-20%,合成時間60分以内で[18F]FRP-170が得られた.毒性試験を実施し,注射液がPET診断に利用できることが示唆された

  51. [18F]標識新規低酸素マーカー [18F]FRP170による脳虚血の画像化に関する基礎研究

    袴塚 崇, 金田 朋洋, 高橋 昭喜, 高井 良尋, 山田 章吾, 丸岡 伸, 和田 裕明, 結城 雅弘, 船木 善仁, 岩田 錬, 井戸 達雄, 辻谷 典彦

    核医学 41 (2) 172-172 2004年5月

    出版者・発行元:(一社)日本核医学会

    ISSN:0022-7854

  52. (O-methyl-[C-11])donepezil, a radiotracer for acetylcholinesterase: Radiochemical synthesis and binding characteristics in the rat brain

    M Kato, Y Funaki, R Iwata, E Sakurai, E Sakurai, K Yanai

    JAPANESE JOURNAL OF PHARMACOLOGY 88 203P-203P 2002年

    出版者・発行元:JAPANESE PHARMACOLOGICAL SOC

    ISSN:0021-5198

  53. 【第30回放射線による制癌シンポジウム 治療効果比向上への新しい展開】 Tumor heterogeneityへの新しい対応 低酸素細胞の画像化 18F化RP-170([18F]FRP-170)による低酸素細胞画像化に関する基礎研究 (癌の臨床)

    高井良尋, 金田朋洋, 梅津篤志, 袴塚崇, 奥本忠之, 村田隆紀, 高井憲司, 藤本圭介, 山田章吾, 和田裕明, 結城雅弘, 船木善仁, 岩田錬, 井戸達夫, 辻谷典彦

    癌の臨床 47 (1) 59-63 2001年

  54. 新しい[18F]標識nitroimidazole誘導体([18F]RP170)による虚血心筋の評価

    金田 朋洋, 高井 良尋, 山崎 哲郎, 丸岡 伸, 高橋 昭喜, 山田 章吾, 船木 善仁, 岩田 錬, 井戸 達雄

    核医学 37 (5) 572-572 2000年9月

    出版者・発行元:(一社)日本核医学会

    ISSN:0022-7854

  55. 乱用薬物の有害性及び依存メカニズムに関する研究 メタンフェタミン急性投与時および,反復投与後の逆耐性現象完成後のラット線条体におけるアセチルコリンの変動 (厚生省S)

    佐藤光源, 豊田洋, 伊藤千裕, 船木善仁, 桜井映子, 谷内一彦, 渡辺建彦

    乱用薬物の有害性及び依存メカニズムに関する研究 平成8年度 1997年

  56. Effects of haloperidol and cocaine pretreatments on brain distribution and kinetics of [11C]methamphetamine in methamphetamine sensitized dog: application of PET to drug pharmacokinetic study.

    NAKAMURA H, HISHINUMA T, TOMIOKA Y, ISHIWATA S, MIZUGAKI M, IDO T, IWATA R, FUNAKI Y, NUMACHI Y

    Nucl. Med. Biol. 24 (2) 165-169 1997年

    DOI: 10.1016/S0969-8051(96)00204-1  

    ISSN:0969-8051

  57. P-A-9-2 向精神薬の体内動態と作用発現に関する研究 XIII : PET による [^<11>C] methamphetamine のサル脳内動態の検討

    中村 仁, 菱沼 隆則, 富岡 佳久, 水柿 道直, 岩田 錬, 船木 善仁, 井戸 達雄, 藤原 竹彦, 谷内 一彦, 伊藤 正敏, 沼知 陽太郎, 吉田 寿美子, 佐藤 光源

    日本病院薬学会年会講演要旨集 6 228-229 1996年8月21日

    出版者・発行元:日本医療薬学会

  58. マグネシウムの生体内動態について

    木村 修一, 川村 美笑子, 井戸 達雄, 中津川 研一, 池田 由美子, 船木 善仁, 岩田 錬

    Biomedical research on trace elements 6 (3) 129-130 1995年12月31日

    ISSN:0916-717X

  59. Present Status of the [18F]FDG Production at CYRIC

    Iwata R., Ishikawa Y., Funaki Y., Naitoh Y., Ido T.

    CYRIC annual report 1995 87-91 1995年

    出版者・発行元:Cyclotron and Radioisotope Center, Tohoku University

    詳細を見る 詳細を閉じる

    開始ページ、終了ページ: 冊子体のページ付け

  60. Alterations in Brain Distribution of [11C]Methamphetamine in Methamphetamine Sensitized Dog

    Mizugaki M., Nakamura H., Hishinuma T., Tomioka Y., Ishiwata S., Suzuki H., Ido T., Iwata R., Funaki Y., Itoh M., Fujiwara T., Yanai K., Sato M., Numachi Y., Yoshida S.

    CYRIC annual report 1994 153-158 1994年

    出版者・発行元:Cyclotron and Radioisotope Center, Tohoku University

    詳細を見る 詳細を閉じる

    開始ページ、終了ページ: 冊子体のページ付け

  61. The effect of the different dietary magー nesium or calsium level on magnesium behavior in mice.,

    M. Kawamura, Y. Ikeda, R. Iwata, Y. Funaki, T. Ido

    Trace Nutr. Res., 12 117-123

︎全件表示 ︎最初の5件までを表示

講演・口頭発表等 26

  1. Separation of Y(III) and Sr(II) from Acid Solutions using a Silica-based HDEHP Adsorbent and Its Medical Application 国際会議

    Seong-Yun Kim, Tatsuya Ito

    GLOBAL2017 2017年9月24日

  2. メチルトリフレートを用いたオンカラムメチオニン合成における放射化学的純度の変化

    林緑也, 石川洋一, 岩田鎌, 谷内一彦

    第55回日本核医学会総会 2015年11月5日

  3. メチルトリフレートを用いたオンカラムメチオニン合成における放射化学的純度の向上

    林緑也, 石川洋一, 岩田鎌, 谷内一彦

    第135年会日本薬学会 2015年3月26日

  4. 高レベル放射性廃液中(HLLW)からの発熱性核種の分離技術の開発

    菊地洋平, 金聖潤

    第134年会日本薬学会 2014年3月27日

  5. PIXE法を用いた加齢変化に伴うラット脳内微量元素の測定

    志村大樹, 高橋弘樹, 松山成男, 山﨑浩道, 石井慶造

    第132年会日本薬学会 2012年3月28日

  6. Production and chemical separation of “No carrier added” iodine-124 from a reusable enriched tellurium-124 dioxide target 国際会議

    Y. Kikuchi, H. Yamazaki, K. Ishii

    第8回日中共同セミナー 2010年10月11日

  7. 超高分解能PET(FINE-PET)で何が見えるか?何ができるか?

    菊池洋平, 山本未央, 横山政宣, 渡邊夕紀子, 小玉哲也, 金井泰和, 畑澤 順, 山崎浩道, 石井慶造

    第4回小動物PET研究会 2010年7月2日

  8. Assesment of new semiconductor animal PET performance in the rodent using [F-18]FDG, [C-11]raclopride, [C-11]doxepin and [C-11]donepezil 国際会議

    Yohei Kikuchi, Koichi Nakazawa, Hiromichi Yamazaki, keizo Ishii

    ヨーロッパ核医学会 2009年10月11日

  9. 超高分解能PETを用いたマウスにおけるヨウ素124標識抗体によるがんの画像化の研究

    山﨑浩道, 堀内逸智, 中沢浩一, 菊池洋平, 石井慶造

    原子力学会 2009年9月16日

  10. ヨウ素124を用いた標識抗体作製における基礎的検討

    堀内逸智, 菊池洋平, 岩田錬, 山﨑浩道, 石井慶造

    第129年会日本薬学会 2009年3月28日

  11. ヨウ素124を用いた標識抗体の作製

    堀内逸智, 菊池洋平, 岩田錬, 山崎浩道, 石井慶造

    第48回日本核医学会総会 2008年10月24日

  12. 半導体検出器を用いた新規動物用PET装置の性能評価

    山﨑浩道, 金井泰和, 菊池洋平, 酒巻学, 岩田錬, 石井慶造

    第128年会日本薬学会 2008年3月28日

  13. 半導体検出器を用いた新規動物用PET装置の性能評価

    金井泰和, 菊池洋平, 酒巻学, 松山成男, 岩田錬, 山崎浩道, 石井慶造

    第47回日本核医学会総会 2007年11月4日

  14. Evaluation of the regional distribution of acetylcholinesterase in the living human brain using [C-11donepezil and PET 国際会議

    Nobuyuki Okamura, Motohisa Kato, Manabu Tashiro, Youichi Ishikawa, Ren Iwata, Kazuhiko Yanai

    米国核医学会 2007年6月2日

  15. ω受容体の可視化を目的とした新規イメージングプローブの開発

    石川洋一, 岩田錬

    第127年会日本薬学会 2007年3月28日

  16. ω受容体の可視化を目的とした新規イメージングプローブの開発

    石川洋一, 岩田錬

    第46回日本核医学会総会 2006年11月9日

  17. Dynamic postron autoradiography法を用いた[18F]fluoroproxyfanの結合特性の評価

    佐藤公彦, 石川洋一, 岩田錬

    第126年会日本薬学会 2006年3月28日

  18. ヒスタミンH3受容体の可視化を目的とした新規PET用イメージングプローブの開発

    佐藤公彦, 石川洋一, 岩田錬

    第45回日本核医学会総会 2005年11月11日

  19. PETを用いた健常者およびアルツハイマー患者における[11C]donepezilの分布評価

    岡村信行, 加藤元久, 田代学, 石川洋一, 岩田錬, 谷内一彦

    第125年会日本薬学会 2005年3月29日

  20. Evaluation of the regional distribution of acetylcholinesterase in the living brain using [11C]donepezil and PET 国際会議

    Okamura, M. Kato, M. Tashiro, Y. Ishikawa, R. Iwata, K. yanai

    第7回国際アルツハイマー・パーキンソン病会議 2005年3月9日

  21. PETを用いた健常者における[11C]donepezilの分布評価

    岡村信行, 加藤元久, 田代学, 石川洋一, 岩田錬, 谷内一彦

    第44回日本核医学会総会 2004年11月4日

  22. Synthesis and evaluation of [11C]donepezil for in vivo visualozation of acetylcholinesterase 国際会議

    N. Okamura, M. Kato, M. Tashiro, R. Iwata, K. yanai

    第6回日中共同セミナー 2004年9月22日

  23. 加齢ラットにおける[11C]donepezilの結合特性の評価

    加藤元久, 岩田錬, 谷内一彦

    第124年会日本薬学会 2004年3月29日

  24. Dynamic postron autoradiography法を用いた[11C]Donepezilの結合特性の評価

    第3回放射性医薬品・画像診断薬研究会 2003年11月28日

  25. Dynamic postron autoradiography法による[11C]Donepezilの結合特性の検討

    加藤元久, 岩田錬, 谷内一彦

    第43回日本核医学会総会 2003年10月27日

  26. Dynamic postron autoradiography法による[11C]Donepezilの結合特性の評価

    加藤元久, 岩田錬, 井戸達雄, 谷内一彦

    第123年会日本薬学会 2003年3月27日

︎全件表示 ︎最初の5件までを表示

社会貢献活動 5

  1. 放射線管理実務セミナー

    2024年1月23日 ~ 2024年1月23日

  2. 放射線管理実務セミナー

    2023年1月24日 ~ 2023年1月24日

  3. 第4回分子イメージングに関する教育研修

    2014年11月27日 ~ 2014年11月28日

    詳細を見る 詳細を閉じる

    RIを用いた分子イメージングに関して講義および実習を通して今後のRI分子イメージング研究・教育を担う人材育成

  4. 放射線業務従事者等のための教育訓練講習会

    2017年5月26日 ~

    詳細を見る 詳細を閉じる

    放射線業務従事者等への教育訓練の講師

  5. 放射線業務従事者等のための教育訓練講習会

    2016年5月27日 ~

    詳細を見る 詳細を閉じる

    放射線業務従事者等への教育訓練の講師

その他 3

  1. 工学部放射線安全工学講義

  2. 医学部保健学科放射化学講義

  3. 薬学部放射化学講義